Poster session II Saturday June 17

Meet-the-Expert Sessions | Simultaneous Sessions | Clinical Trial Update Session | Science in Progress Session | Hematology-in-Focus Sessions | Lunch Debates | EHA/ASH Joint Symposium | EHA Business Meeting | Plenary Session I | Presidential Symposium - 6 best abstracts | Scientific Working Groups | Poster Session II


Poster presentation during Poster-walks from 17.45 - 19.00 hours Poster area (behind Exhibition)

POSTER-WALKS
Poster-walks will be repeated this year due to great success. This event was introduced in order to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators and interested congress participants. Poster-walks will be organized during the poster sessions on Friday, June 16 and Saturday, June 17 (17.45 - 19.00 hours). The poster area is located next to exhibition. Poster authors, moderators and interested congress participants are kindly requested to be present at the first poster in their poster session at the beginning of the presentation time (17.45 hours). Snacks and drinks will be served.

POSTER SESSION II

17.45 - 19.00 hours, Poster area (behind Exhibition)

TRANSFUSION MEDICINE

0536 "BLOOD-SHOT EYES": AUTOLOGOUS SERUM EYE DROPS FOR GRAFT-VERSUS- HOST DISEASE AND OTHER DISORDERS
S.D.J. Gibbs, J. Pankhurst, M. Daniell, K. Boeters, S. Winzar, E.M. Wood (Australian Red Cross Blood Service, Melbourne, Australia)
 
0537 ERYTHROID CRISIS CAUSED BY PARVOVIRUS B19 TRANSMITTED VIA RED BLOOD CELL TRANSFUSION - ITS DIRECT DETECTION BY PCR DIRECT SEQUENCING METHOD
Y.T Tsukada, Y.K. Yokoyama, A.I. Ishida, M.H. Handa, Y.I. Ikeda, S.O. Okamoto, M.K. Kizaki (KEIO University School of Medicine, Tokyo, Japan)
 
0538 USE OF TAGVHD WARNINGS IN PATIENTS RECEIVING PURINE ANALOGUE CHEMOTHERAPY
F.J. Cutler, C. Niciu, J.A. Murphy, R.L. Soutar (Scottish National Blood Transfusion Serv, Glasgow, United Kingdom)
 
0539 FACTORS DETERMINING THE RISK OF SEVERE (WHO GRADE 3 AND 4) HEMORRHAGE IN HEMATOLOGIC PATIENTS
W. Jedrzejczak, E. Drozd (Medical University of Warsaw, Warsaw, Poland)
 
0540 LONG-TERM ERYTHRO-EXCHANGE IN THE TREATMENT AND PREVENTION OF SEVERE SICKLE CELL DISEASE RELATED COMPLICATIONS IN SICILY
T. Lombardo, P. Fazzino, S. Pennisi (Osp. S. Bambino, Catania, Italy)
 
0541 HAEMOVIGILANCE FOR THE TRANSFUSION THERAPY OF PATIENTS WITH THALASSAEMIA
C. Politis, A. Manitsa, E. Zervou, O. Marantidou, M. Hatzitaki, G. Martinis, L. Papayiannis, E. Kantidaki, D. Damaskos, C. Richardson (G.H. Athens "G. Gennimatas", Athens, Greece)
 
0542 PROGRESSIVE MEMBRANE AND CYTOSKELETON ACCUMULATION OF OXIDIZED/DENATURED HEMOGLOBIN IN STORED RED BLOOD CELLS
A. Kriebardis, M. Antonelou, K. Stamoulis, E. Economou-Petersen, L. Margaritis, I. Papasideri (University of Athens, Athens, Greece)
 
0543 MEMBRANE AND CYTOSKELETON PROTEIN CARBONYLATION IN NON-LEUKODEPLETED CPDA-PRESERVED RED BLOOD CELLS
A. Kriebardis, M. Antonelou, K. Stamoulis, E. Economou-Petersen, L. Margaritis, I. Papassideri (University of Athens, Athens, Greece)
 
0544 PLATELETS RECOVERY AND TRANSFUSION NEEDS AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC PERIPHERAL BLOOD STEM CELL (PBSC) TRANSPLANTATION
T. Prebet, P. Ladaique, M. Ferrando, C. Chabannon, C. Faucher, S. Furst, H. De Lavallade, J. El-Cheikh, J.A. Gastaut, D. Blaise, M. Mohty (Institut Paoli Calmettes, Marseille, France)
 
0545 CHANGES OF HAEMOSTASIS INDUCED BY LDL-APHERESIS
M.N. Blazek, M. Blaha, J. Maly, V. Blaha, M. Cermanova, M. Pecka, L. Slovacek (Faculty Hospital, Charles University, Hradec Kralove, Czech Republic)
 
0546 METABOLIC MARKERS AND FUNCTIONAL PARAMETERS OF PLATELET CONCENTRATES COLLECTED BY MULTICOMPONENT APHERESIS WITH TWO DIFFERENT CELL SEPARATORS
S. Macher, K. Schallmoser, S. Sipurzynski, K. Rosskopf, R. Gilli, E. Gruber, G. Lanzer (University of Graz, Graz, Austria)
 
0547 IVIG AND RITUXIMAB ALLOWS SUCCESSFUL SOLID ORGAN TRANSPLANTATION IN PATIENTS WITH A POSITIVE CROSSMATCH AND DONOR SPECIFIC ANTI-HLA ANTIBODIES
S.D.J. Gibbs, S.J. Cohney, M. Haeusler, B. Tait, R. Walker, M. Finlay, T. Langdren, M. Wood, C. Hogan (Australian Red Cross Blood Service, Melbourne, Australia)
 
0548 TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE IN FOUR IMMUNOCOMPETENT PATIENTS
T.A. Atamer, M.N. Yenerel, F. Aydin, N. Eskinazi, R. Diz-Kucukkaya, B. Artim- Esen, O. Dogan, M. Agan (Istanbul University, Capa-istanbul, Turkey)
 
0549 THE CELLULAR COMPONENTS INDUCED IMMUNOSUPPRESSION VIA REGULATORY T CELLS IN ALLOGENEIC TRANSFUSION
P. Jeong, P. Jang, B. Cho, N. Chung, H. Kim, C. Han (The Catholic University of Korea, Inchon, South-Korea)
 
0550 IMPLEMENTATION OF HAEMOVIGILANCE SYSTEM FOCUSSING IN DONORS COLLECTION
V. Recasens, A. Rubio-Martinez, J.F. Lucia, M. Giralt, V. Solano (Miguel Servet University Hospital, Zaragoza, Spain)
 

APLASTIC ANEMIA

 
0551 A STUDY OF HLA AND KIR GENES IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA PATIENTS
F. Alfinito, M.L. Lombardi, E. Cosentini, M. Sica, R. Camerlingo, D. Aufiero, A. Risitano, G. Ruggiero, G. Terrazzano (University of Naples "Federico II", Napoli, Italy)
 
0552 EXPRESSION PATTERNS OF GLYCOSYLPHOSPHATIDYLINOSITOLANCHORED PROTEINS (GPI-AP) THROUGHOUT THE DIFFERENT NORMAL BONE MARROW CELL MATURATION PATHWAYS: A FRAME OF REFERENCE FOR UNDERSTANDING PNH
M. Hernández-Campo, J. Almeida, S. Matarraz, M. De Santiago, M.L. Sánchez, A. Orfao (University of Salamanca, Salamanca, Spain)
 
0553 PREGNANCY-INDUCED PURE RED-CELL APLASIA, A DISTINCT SYNDROME
A. Laber, K. Moffett, A. Choudry (University of Louisville, Louisville, Ky, USA)
 
0554 IMMUNOSUPPRESSIVE THERAPY WITH ANTILYMPHOCYTE GLOBULIN (ALG), CYCLOSPORINE AND PREDNISOLONE IN THE TREATMENT OF APLASTIC ANEMIA - A SINGLE CENTRE EXPERIENCE
B. George, V. Mathews, A. Viswabandya, A. Srivastava, M. Chandy (Christian Medical College, Vellore, Vellore, Tamilnadu, India)
 
0555 SEVEN TURKISH PATIENTS WITH NIJMEGEN BREAKAGE SYNDROME: CLINICAL CHARACTERISTICS AND MUTATION ANALYSIS
C. Ucar, U. Çaliskan, H. Gulen, M. Tekin, A. Zamani, A. Erbay, E. Kazanci, C. Vergin (Selcuk University Meram Medical Faculty, Konya, Turkey)
 
0556 BONE MARROW EXPRESSION PROFILE OF RAS, P53, AND MDM2 GENES IN CYTOPENIC DISORDERS
E. Schulz, I. Lorand-Metze, F.F. Costa, S.C. Costa, S.T.O. Saad (State University of Campinas Brazil, Dresden, Germany)
 

ANEMIA / RED BLOOD CELLS II

 
0557 REDUCED INSULIN SECRETION IN NORMOGLYCEMIC PATIENTS WITH ß-THALASSAEMIA MAJOR
N. Angelopoulos, A. Zervas, S. Livadas, I. Adamopoulos, D. Giannopoulos, A. Goula, G. Tolis (Hippocratio Hospital, Athens, Greece)
 
0558 RECOMBINANT ERYTHROPOIETIN AS TREATMENT FOR THE HYPOREGENERATIVE ANEMIA OF HEMOLYTIC DISEASE OF THE NEWBORN
H. Donato, G. Schvartzman, C. García, N. Vain (Bio Sidus, Buenos Aires, Argentina)
 
0559 RET-HE - RETICULOCYTE HEMOGLOBIN EQUIVALENT - IN PATIENTS WITH VITAMIN B12 AND/OR FOLATE DEFICIENCY
A.F. Remacha, C. Canals, M.P. Sarda, M.T. Royo, E. Rojas, J.M. Piazuelo, M.A. Romero (Hospital de Sant Pau, Barcelona, Spain)
 
0560 DORSAL SURAL NERVE CONDUCTION STUDY IN VITAMIN B12 DEFICIENCY WITH MEGALOBLASTIC ANEMIA
B. Turgut, N. Turgut, S. Akpinar, K. Balci, G.E. Pamuk, E. Tekgunduz, M. Demir (Trakya Universitiy School of Medicine, Edirne, Turkey)
 
0561 ANTI-CARDIOLIPIN, ANTI-ß2 GLYCOPROTEIN I, AND ANTI-PHOSPHATIDYLSERIN AUTO-ANTIBODIES AND THE RISK OF SICKLE CELL ANEMIA
W.Y. Almawi, I.K. Al-Absi, A.M. Al-Subaie, G. Ameen, N.A. Fawaz (Arabian Gulf University, Manama, Bahrain)
 
0562 ERYTHROPOIETIN PRODUCED BY A HUMAN CELL LINE HAS ONLY TRACE LEVELS OF POTENTIALLY IMMUNOGENIC N-GLYCOLYLNEURAMINIC ACID RESIDUES
Z. Shahrokh, S. Flatman, M. Davies, A. Baycroft, M. Heartlein (Shire Human Genetic Therapies Inc, Cambridge, USA)
 
0563 STUDY OF THE INNOVATIVE PARAMETERS RET-Y & RBC-Y IN PATIENTS WITH HYPOCHROMIC, MICROCYTIC ANEMIA
A. Agorasti, D. Konstantinidou (General Hospital of Xanthi, Xanthi, Greece)
 
0564 LEBANESE G6PD DEFICIENCY: EVALUATION OF THE NEONATAL SCREENING AND PHENOTYPE DESCRIPTION.
C. Khayat Djambas, M.T. Abi Wardé, I. Khneisser, J. Loiselet, A. Megarbane (Hotel Dieu de France Hospital, Beirut, Lebanon)
 
0565 MEASURE OF RETICULOCYTE HAEMOGLOBINISATION BY WHOLE BLOOD HAEMATOLOGY ANALYSERS: CORRELATION OF CHR (BAYER ADVIA 120) WITH RET-HE (SYSMEX XE-2100)
I. Papassotiriou, M. Nicolaou, C. Tsitsikas, S. Polychronopoulou, A. Stamoulakatou (Aghia Sophia Children's Hospital, Athens, Greece)
 
0566 EVALUATION OF MYOCARDIAL IRON DEPOSITION ASSESSED WITH M.R.I. IN YOUNG THALASSAEMIC PATIENTS RECEIVING ONE YEAR OF DEFERASIROX VERSUS DEFEROXAMINE
A. Christoforidis, I. Tsatra, K. Karasmanis, E. Zevgaridou, A. Koussi, I. Tsitourides, M. Athanassiou-Metaxa (Aristotle University of Thessaloniki, Thessaloniki, Greece)
 
0567 DIVERSE MOLECULAR DEFECTS ASSOCIATED WITH IDIOPATHIC ERYTHROCYTOSIS REFLECT THE HETEROGENEITY OF THIS DISORDER
M.J. Percy, M.J. Percy, F.G.C. Jones, T.R.J. Lappin, M.F. McMullin (Belfast City Hosptial, Belfast, United Kingdom)
 
0568 CHARACTERISATION OF BONE MARROW POSITIVE MITOGEN-STIMULATED DIRECT ANTIGLOBULIN TEST IN PATIENTS WITH REFRACTORY ANEMIA
F.G. Imperiali, A. Zaninoni, M. Colombi, A. Iurlo, A. Zanella, W. Barcellini (Fondazione IRCCS Policlinico, Milano, Italy)
 
0569 SERUM PRO-HEPCIDIN AND IRON STATUS IN THALASSAEMIA
A. Meo, L. Duca, P. Delbini, L. Nava, L. Zanghě, M.A. La Rosa, A. Crifň, M.D. Cappellini (Policlinico "G. Martino" Medical School, Messina, Italy)
 
0570 THE ABSOLUTE RETICULOCYTE COUNTS AND IRON OVERLOAD CORRELATE WITH PULMONARY HYPERTENSION OBSERVED IN PATIENTS WITH SICKLE CELL/BETA THALASSEMIA
E. Voskaridou, G. Tsetsos, A. Tsoutsias, E. Spyropoulou, E. Terpos (Thalassemia Center, Laikon Gen. Hospital, Athens, Greece)
 
0571 CHARACTERISATION OF A DOUBLE MUTATION, THE NOVEL PRO92HIS AND PREVIOUSLY DESCRIBED GLU255-, OF NADH-CYTOCHROME B5 REDUCTASE ASSOCIATED WITH APPARENT TYPE I RCM
M.J. Percy, L.J. Crowley, D.M. Layton, T.R.J. Lappin, M.J. Barber (Belfast City Hosptial, Belfast, United Kingdom)
 
0572 COST ASSESSMENT OF BETA THALASSEMIA MAJOR: THE ITHACA STUDY
L.G. Mantovani, S. Ravera, M.D. Cappellini (Center of Pharmacoeconomics Univer Milan, Milan, Italy)
 
0573 A FAMILY WITH A MILD PHENOTYPE DESPITE MULTIPLE MUTATIONS IN THE ALPHA- AND BETA-GLOBIN GENE CLUSTER
K.M.K. de Vooght, R. van Wijk, G. Rijksen, W.W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)
 
0574 GENOMIC INSTABILITY IN SICKLE CELL DISEASE PATIENTS USING HYDROXYREA ASSESSED BY ALKALINE SINGLE-CELL GEL ELECTROPHORESIS ASSAY
J.R. Friedrisch, L.M.R. Silla, S. Maluf, M. Mergener, T. Pollo, M. Kayser, C.M. Bittar, M.A.L. da Silva, V.S. de Valim, R.T. de Souza (Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil)
 
0575 DISTINCT PHENOTYPIC EXPRESSION IN PATIENTS WITH THE HYPERUNSTABLE ALPHA-CHAIN VARIANTS HB TAYBEE (ALPHA1CD38/39DELACC; THR>0) AND HB HERAKLION (ALPHA1CD36/37DELCCC; PRO>0)
I. Papassotiriou, E. Kanavakis, D. Liapi, A. Tsilimigaki, A. Stamoulakatou, M. Mavrokosta, J. Traeger-Synodinos (Aghia Sophia Children's Hospital, Athens, Greece)
 
0576 EPOETIN DELTA, ERYTHROPOIETIN PRODUCED BY A HUMAN CELL LINE, IS EFFECTIVE IN THE TREATMENT OF RENAL ANAEMIA
R. Pratt (Shire Pharmaceuticals, Wayne, USA)
 

CYTOGENETICS AND MOLECULAR CYTOGENETICS

 
0577 ONCOGENIC DEREGULATION OF HOXA GENES BY CHROMOSOMAL REARRANGEMENTS IN T-CELL LYMPHOBLASTIC LEUKEMIAS (T-ALL)
E. Clappier, J.M. Cayuela, A. Baruchel, E. Morgado, W. Cuccuini, A. Regnault, A. Baruchel, H. Dombret, C. Lavau, F. Sigaux, J. Soulier (Hôpital Saint-Louis, Paris, France)
 
0578 CORRELATION BETWEEN CHROMOSOMAL ABNORMALITIES AND IMMUNOHISTOCHEMICAL PROFILE IN DIFFUSE LARGE-B CELL LYMPHOMAS (DLBCL) REVEALS DISTINCT LYMPHOMAGENESIS PATHWAYS WITH CLINICOPATHOLOGIC SIGNIFICANCE AND PROGNOSTIC VALUE
F. Jardin, J.M. Picquenot, P. Ruminy, C. Bastard, M. Cornic, V. Rainville, F. Parmentier, A Stamatoullas, S. Leprętre, P. Lenain, N. Contentin, G. Buchonnet, H. Tilly (Centre Henri Becquerel, Rouen, France)
 
0579 PDGFRB FUSES TO TPM3 IN THE T(1;5)(Q23;Q33) OF CHRONIC EOSINOPHILIC LEUKEMIA AND TO NDE1 IN THE T(5;16)(Q33;P13) OF CHRONIC MYELOMONOCYTIC LEUKAEMIA
R. Rosati, R. La Starza, A. Bardi, L. Luciano, C. Matteucci, V. Pierini, S. Romoli, B. Crescenzi, F. Pane, A. Cuneo, M.F. Martelli, J. Cools, P. Marynen, C. Mecucci (Hematology, Perugia, Italy)
 
0580 A DNA-BASED RQ-PCR SCREENING ASSAY FOR RUNX1 COPY NUMBER CHANGES IN CHILDHOOD B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)
A. Haas (CCRI, Vienna, Austria)
 
0581 META-ANALYSIS OF 966 B-CELL NEOPLASMS WITH 8Q24 ABERRATIONS IDENTIFIES DISTINCT CYTOGENETIC ABERRATION PATTERNS OF BURKITT AND NON-BURKITT LYMPHOMAS
M. Baudis, R. Siebert (University of Florida, Gainesville, USA)
 
0582 MOLECULAR CHARACTERIZATION OF DISTINCT HOT SPOT REGIONS ON CHROMOSOME 7Q IN MYELOID LEUKEMIAS
R.T. Obermiller, M. Habdank, F.G. Rücker, S. Miller, S.W. Scherer, H. Döhner, K. Döhner (University Hospital of Ulm, Ulm, Germany)
 
0583 SERIAL ANALYSIS OF CHROMOSOME ABERRATIONS IN MULTIPLE MYELOMA: HIGH PREVALENCE OF STRUCTURAL ABNORMALITY OF CHROMOSOME 1 DURING DISEASE PROGRESSION
K.L. Wu, H.B. Beverloo, P. Sonneveld (Erasmus MC, Rotterdam, The Netherlands)
 
0584 THE APOC1 GENE LOCATED ON 19Q13.2 IS RECURRENTLY GAINED AND OVEREXPRESSED IN ACUTE MYELOID LEUKEMIA
S. Alvarez, J. Suela, C. Largo, A. Cascón, D. Blesa, M.J. Calasanz, M.D. Odero, J.C. Cigudosa (CNIO, Madrid, Spain)
 
0585 CHROMOSOMAL ABERRATIONS ARE DETECTED IN 80% OF CLL PATIENTS BY METAPHASE CYTOGENETICS: A STUDY OF 132 CLL CASES WITH CORRELATION TO FISH, IGVH STATUS, AND CD38 EXPRESSION
S. Dicker, S. Schnittger, T. Haferlach, W. Kern, C. Schoch (MLL Munich Leukemia Laboratory GmbH, Munich, Germany)
 
0586 T(4;11) PATIENTS REVISED: T(4;11) PATIENTS CARRY TWO MLL FUSION ALLELES
C. Meyer, E. Kowarz, T. Dingermann, T. Klingebiel, R. Marschalek (Johann Wolfgang Goethe-University, Frankfurt/main, Germany)
 
0587 FISH-MLL ABNORMALITIES IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA AND ASSOCIATION WITH FLT3 AND MLL INTERNAL DUPLICATION
E. Giugliano, G. Rege-Cambrin, P. Scaravaglio, D. Diverio, A. Serra, M. Mancini, V. Brunetto, G. Ferranti, G. Mattioli, C. Fava, M. Fimognari, S. Ulisciani, F. Pane, F. Lo Coco, G. Saglio (University of Torino, Orbassano, Torino, Italy)
 
0588 A NEW CRYPTIC MOLECULAR LESION UNDERLIES 6P CHANGES IN SECONDARY ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME (AML/MDS)
R. La Starza, A. Aventin, C. Matteucci, B. Crescenzi, S. Romoli, N. Testoni, V. Pierini, S. Ciolli, C. Sambani, A. Locasciulli, M. Lafage-Pochitaloff, M.F. Martelli, P. Marynen, C. Mecucci (Hematology, University of Perugia, Perugia, Italy)
 
0589 CYTOGENETIC AND FISH STUDY IN 203 B-CLL PATIENTS
M. Holzerova, H. Pospisilova, T. Papajik, R. Urbanova, Z. Pikalova, R. Plachy, K. Indrak, M. Jarosova (University Hospital, Olomouc, Czech Republic)
 
0590 A MOLECULAR CYTOGENETIC STUDY OF MANTLE CELL LYMPHOMA AT DIAGNOSIS AND FOLLOW-UP: EVIDENCE FOR A "TEMPORALLY ORDERED" CYTOGENETIC EVOLUTION?
S.I. Papadhimitriou, A. Davea, I. Savvidou, G. Paterakis, E. Goumakou, E. Griva- Kritikou, G. Androutsos, D. Pavlidis, T. Marinakis, N.I. Anagnostopoulos, M Georgiakaki ("G. Gennimatas" Athens Regional General, Athens, Greece)
 
0591 PROGNOSTIC SIGNIFICANCE OF COMPLEX CHROMOSOMAL REARRANGEMENTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
L. Babicka, Z. Zemanova, L. Pavlistova, J. Brezinova, J. Moravcova, H. Klamova, K. Michalova (General Faculty Hospital and 1st Med Fac, Prague 2, Czech Republic)
 
0592 TRANSLOCATION T(9;14)(P13;Q32) IN THREE CASES OF SPLENIC MARGINAL ZONE LYMPHOMA
C. Baró, M. Salido, B. Espinet, A. Domingo, I. Granada, A. Carrió, V. Romagosa, F. Millŕ, L.I. Colomo, E. Campo, S. Serrano, F. Solé (Hospital del Mar, Barcelona, Spain)
 
0593 I-FISH ANALYSIS OF IMMUNOFLUORESCENTLY LABELED PLASMA CELLS IN PATIENTS WITH MULTIPLE MYELOMA
L. Pavlistova, Z. Zemanova, J. Skuhrovcova, I. Spicka, E. Gregora, A. Dohnalova, K. Michalova (General Faculty Hospital and 1st Med Fac, Prague 2, Czech Republic)
 
0594 DETECTION OF STRUCTURAL ABERRATIONS OF CHROMOSOME 7 IN MYELOID MALIGNANCIES USING COMBINATION OF MOLECULAR CYTOGENETIC TECHNIQUES
J. Brezinova, Z. Zemanova, J. Melichercikova, L. Babicka, M. Siskova, J. Cermak, K. Michalova (Institute of Hematology and Blood Transf, Prague 2, Czech Republic)
 
0595 T(5;12)(Q23-31;P13) WITH ETV6-ACSL6 GENE FUSION IN POLYCYTHEMIA VERA
A. Murati, J. Adélaďde, V. Gelsi-Boyer, A. Etienne, D. Sainty, L. Xerri, N. Vey, H. Fezoui, D. Birnbaum, M. Chaffanet, M.J. Mozziconacci (Institut paolicalmettes, Marseille, France)
 
0596 ADDITIONAL CHROMOSOMAL ABNORMALITIES IN PH-POSITIVE CML DE NOVO: A MULTICENTER STUDY
Z. Salamanczuk, B. Pienkowska-Grela, E. Wawrzyniak, I. Kardas, M. Iliszko, B. Mucha, M. Jakóbczyk, E. Duszenko, O. Haus (Medical College, Jagiellonian University, Krakow, Poland)
 

GENOMICS AND PROTEOMICS

 
0597 FUNCTIONAL ANALYSIS OF CANDIDATE GENES LOCALISED IN 13Q14.3, A REGION COMMONLY AFFECTED IN B-CLL
C. Tschuch, A. Pscherer, S. Wolf, M. Hahn, P. Lichter, D. Mertens (German Cancer Research Center, Heidelberg, Germany)
 
0598 VALUE OF PROTEOMIC SCREENIG FOR PREDICTION OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
E.M. Weissinger, H. Zakaria, E. Schiffer, H. Mischak, B. Hertenstein, A. Ganser (Hannover Medical School, Hannover, Germany)
 
0599 FINE-MAPPING THE HISTONE CODE AT 13Q14.3, A CRITICAL REGION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
M. Ruppel, D. Mertens, P. Lichter (German Cancer Research Center, Heidelberg, Germany)
 
0600 XLN PREDISPOSES TO MYELOID MALIGNANCIES BUT GAIN OF FUNCTION WASP MUTATIONS ARE NOT FOUND IN MYELODYSPLASIA OR AML
K.A. Beel, E. Schollen, A. Uyttebroeck, G. Verhoef, H. Demuynck, K. Devriendt, P. Vandenberghe (KULeuven, Leuven, Belgium)
 
0601 INTRONIC MICRO RNA ANALYSIS IN LEUKEMIA REVEALS COORDINATED EXPRESSION WITH HOST GENES
S. San-Marina, F. Suarez Saiz, M. Minden (Ontario Cancer Institute, Toronto, Canada)
 
0602 IN VITRO AND IN VIVO VALPROIC ACID RESPONSE SIGNATURES IN ADULT ACUTE MYELOID LEUKEMIA
L. Bullinger, M. Richter, K. Döhner, F. G. Rucker, C. Scholl, S. Frohling, R.F. Schlenk, J.R. Pollack, H. Döhner, M. Schmid (University of Ulm, Ulm, Germany)
 
0603 GENOMIC APPROACH TO UNDERSTAND THE MECHANISMS INVOLVED IN BCR-ABL-MEDIATED RESISTANCE TO APOPTOSIS
A.E.B. Bueno-da-Silva, G. Brumatti, F.A. Castro, J.F. Jacysyn, L.R. Lopes, P.R. Tobo, R.Z. Vęncio, C.A. Moreira-Filho, O.K. Okamoto, G.P. Amarante-Mendes (ICBUSP, Săo Paulo, Brazil)
 
0604 NOVEL TRANSMEMBRANE MEGAKARYOCYTE PROTEINS IDENTIFIED BY COMPARATIVE GENE EXPRESSION PROFILING OF IN VITRO DIFFERENTIATED HUMAN MEGAKARYOCYTES AND ERYTHROBLASTS
D.C. Thijssen-Timmer, I. C. Macaulay, M.R. Tijssen, A. Gusnanto, M. Steward, B. Tom, P. Carr, C. Voermans, I.W. de Jong, F. Dudbridge, C.E. van der Schoot, J.J. Zwaginga, N.A. Watkins, W.H. Ouwehand (Sanquin Research, Amsterdam, The Netherlands)
 
0605 IDENTIFICATION OF METHYLATED PROMOTERS IN THE OCI/AML2 ACUTE MYELOGENOUS LEUKEMIA CELL LINE USING CPG MICROARRAYS
F. Suarez Saiz, S. San-Marina, M. Minden (University of Toronto/UHN, Toronto, Canada)
 
0606 EXPRESSION SIGNATURE OF GENES ASSOCIATED WITH TELOMERE-TELOMERASE COMPLEX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE LEUKEMIA: TEP1 GENE IS SURPRISINGLY UPREGULATED IN PROGRESSION OF MDS AND IN LEUKEMIC CELLS
H. Zizkova, S. Vcelikova, J. Cermak, J. Maaloufova, R. Neuwirtova, Z. Sieglova (Inst.of Hematology and Blood Transfusion, Prague 2, Czech Republic)
 
0607 TEN NOVEL MUTATIONS IN THE HMBS GENE RESPONSIBLE FOR ACUTE INTERMITTENT PORPHYRIA
E. Di Pierro, V. Besana, V. Brancaleoni, S. Ausenda, D. Tavazzi, M.D. Cappellini (University of Milan-Policlinico Hospital, Milan, Italy)
 
0608 ASSOCIATION OF HUMAN PLATELET ALLOANTIGENS (HPA) 1, HPA2, HPA3, HPA4, AND HPA5 ALLELES AND GENOTYPES WITH SICKLE CELL ANEMIA
W.Y. Almawi, A.M. Al-Subaie, N.A. Fawaz, I.K. Al-Absi, S. Saidi, N. Mahdi, K. Al-Ola (Arabian Gulf University, Manama, Bahrain)
 
0609 GENOTYPE AND CLONAL EVOLUTION IN CHILDHOOD ACUTE LEUKEMIA CASES
S. Bungaro, M. Raghavan, J. Irving, R. Mura, B.D. Young, A. Hall, A. Biondi, G. Cazzaniga, (Centro Ricerche Tettamanti, Monza, Italy)
 
0610 IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS IN ACUTE MYELOID LEUKAEMIA USING A PHOSPHOPROTEOMIC STRATEGY
C. Craddock, M. Griffiths, M. Wakelam (Queen Elizabeth Hospital, Birmingham, United Kingdom)
 
0611 EXPRESSION OF TGFB1 GENES AND THEIR RECEPTOR TYPES I, II AND III IN LYMPH NODES FROM PATIENTS WITH NON-HODGKINS LYMPHOMAS
D.W. Woszczyk, J. Gola, T. Gasinska, T. Urbanek, D. Ziaja, W. Kuczmik, U. Mazurek (Medical University of Silesia, Katowice, Poland)
 

NON-HODGKIN'S LYMPHOMA - EXPERIMENTAL

 
0612 GENE EXPRESSION PROFILING OF PRIMARY HODGKIN/REEDSTERNBERG (HRS) CELLS AND THEIR RELATIONSHIP WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL)
E. Tiacci, V. Brune, S. Eckerle, G. Mechtersheimer, A. Bräuninger, M.L. Hansmann, R. Küppers (Tumor Research, Essen, Germany)
 
0613 PERIFOSINE, AN ORAL BIOACTIVE NOVEL AKT INHIBITOR, INDUCES ANTITUMOR ACTIVITY IN WALDENSTROM MACROGLOBULINEMIA
X.L. Leleu, X.J. Jia, H.N. Ngo, H.E. Hatjiharisi, A.H. Ho, D.S. Santos, X.L. Xu, H.Z. Hunter, A.S.M. Moreau, S.J. Soumerai, D.E. Dimmock, K.T. Kiziltepe, H.T. Hideshima, A.K. Anderson, T.S. Treon, G.I. Ghobrial (Dana-farber cancer institute, Boston, USA)
 
0614 PRECLINICAL PHARMACOLOGY AND IN VITRO CHARACTERIZATION OF PR- 171, A NOVEL INHIBITOR OF THE 20S PROTEASOME
C.J. Kirk, M. Bennett, T. Buchholz, S. Demo, M. Ho, J. Jiang, G. Laidig, E. Lewis, F. Parlati, K. Shenk, M. Smyth, C. Sun, M. Vallone, T. Woo, C. Molineaux (Proteolix, South San Francisco, Ca, USA)
 
0615 ANALYSIS OF DELTA AND GAMMA T-CELL RECEPTOR GENES IN MYCOSIS FUNGOIDES AND SÉZARY SYNDROME
S. Pulini, G. Goteri, A.R. Scortechini, S. Pulini, R. Capretti, A. Tassetti, A. Stronati, S. Mulattieri, A. Filosa, D. Stramazzotti, R. Ranaldi, G. Fabris, P. Leoni (Clinic of Hematology, Ancona, Italy)
 
0616 IMMUNOGLOBULIN V GENES IN WALDENSTROM'S MACROGLOBULINEMIA REVEAL ECTOPIC SOMATIC MUTATIONS BUT NO GLYCOSYLATION MOTIFS
S. Sahota, I. Hamid, G. Babbage, M. Townsend, F. Forconi, F.K. Stevenson (University of Southampton, Southampton, United Kingdom)
 
0617 IDENTIFICATION OF POTENTIAL PROGNOSTIC MICRORNAS IN DIFFUSE LARGE B CELL LYMPHOMA BY EXPRESSION PROFILING
C.H. Lawrie, S. Soneji, C.D.O. Cooper, C.S.R. Hatton (University of Oxford, Oxford, United Kingdom)
 
0618 EVIDENCE FOR A PATHOPHYSIOLOGICAL ROLE OF CYSTEINYL LEUKOTRIENES IN HODGKIN LYMPHOMA
N.O. Sjöberg, F. Schain, Y. Tryselius, L. Backman, M. Malec, A. Porwit-Mac Donald, M. Björkholm, H.E. Claesson (Karolinska University Hospital and Insti, Stockholm, Sweden)
 
0619 HUMAX-CD20, A NOVEL FULLY HUMAN ANTI-CD20 MONOCLONAL ANTIBODY: BIOLOGICAL PROPERTIES
W.J.M. Mackus, J.L. Teeling, J.H.N. van den Brakel, L.J.J.M. Wiegman, W.K. Bleeker, T. Vink, M.E. Munk, M. Folden Flensburg, J.W. Slootstra, M.J. Glennie, P.W.H.I. Parren, J.G.J. van de Winkel (Genmab BV, Utrecht, The Netherlands)
 
0620 THE INFLUENCE OF INTERLEUKIN- 10 (IL-10) PROMOTER GENE POLYMORPHISM ON THE OCCURRENCE OF NON HODGKIN LYMPHOMA (NHL) IN SUBJECTS INFECTED WITH HEPATITIS C VIRUS (HCV)
A. de De Renzo, M. Capasso, F. Perna, E. Persico, C. Marzocchella, A. Iolascon, M. Persico (University of Naples, Naples, Italy)
 
0621 ALEMTUZUMAB FOR THE TREATMENT OF SÉZARY SYNDROME: CLINICAL AND IMMUNOLOGIC FINDINGS IN 10 PATIENTS
M. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, T. Fierro, F. Lisa (University of Turin, Torino, Italy)
 
0622 LENALIDOMIDE INHIBITS PROLIFERATION OF THE CHROMOSOME 5 MUTANT HEMATOPOIETIC TUMOR CELL LINE NAMALWA CSN.70 AND INTERFERES WITH RECEPTOR SIGNALING THROUGH THE SHC/GRB2/GAB1/AKT PATHWAY
A. Gandhi, J. Kang, S. Naziruddin, A. Parton, P. Schafer, D. Stirling (Celgene Corporation, Summit, USA)
 
0623 DETERMINATION OF LYTIC PHASE CELLS AND INTEGRATION STATUS OF EPSTEIN-BARR VIRUS INFECTED CELLS LINES
C. Uphoff, R.A.F. MacLeod, S.A. Denkmann, M. Kaufmann, H.G. Drexler (DSMZ - German Collect. of Microorganisms, Braunschweig, Germany)
 
0624 UTILITY OF FLOW CYTOMETRIC SCREENING ON FINE-NEEDLE ASPIRATES IN THE DIAGNOSIS OF CHRONIC LYMPHOPROLIFERATIVE DISORDERS
S. Susana, M.C. Garcia Macias, J. Almeida, A. López, R. Rivas, A. Orfao (Centro de Investigación del Cancer Salam, Salamanca, Spain)
 
0625 ANAPLASTIC LARGE-CELL LYMPHOMA-A RETROSPECTIVE MULTICENTRIC CLINICAL AND PATHOLOGICAL STUDY
C. Dobrea, A.C. Colita, A. Simion, D. Vasilache, V. Enache, L. Caban, A. Tatic, E. Niculescu-Mizil, O. Georgescu, M. Vasilica, A.D. Moicean, I. Ursuleac, R. Stoia, D. Coriu, D. Colita (Fundeni Clinical Institute, Bucharest, Romania)
 
0626 EXPRESSION OF CD52 IN T-CELL AND NK/T-CELL LYMPHOMAS
S.S. Chuang (Chi-Mei Medical Center, Yung-kang City, Taiwan)
 
0627 SPLENIC MARGINAL-ZONE LYMPHOMA: ONE OR MORE ENTITIES? A HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND MOLECULAR STUDY OF 42 CASES
T. Papadaki, K. Stamatopoulos, C. Belessi, E. Pouliou, A. Parasi, V. Douka, A. Hadzidimitriou, N. Laoutaris, A. Fassas, A. Anagnostopoulos, D. Anagnostou (Evangelismos Hospital, Athens, Greece)
 
0628 REAL-TIME QUANTITATIVE PCR (RQ-PCR) AND FOUR COLOUR FLOW CYTOMETRY (FC) FOR MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT OF MANTLE CELL LYMPHOMA (MCL)
P. Gameiro, M. Sebastiăo, P. Lucio, T. Faria, J. Cabeçadas, A. Parreira, M.G. Silva (Portuguese Institute of Oncology, Lisbon, Portugal)
 
0629 PHARMACOGENOMIC APPROACH IN WALDENSTROM’S MACROGLOBULINEMIA AND SMALL LYMPHOCYTIC LYMPHOMA PATIENTS: HCNT1 EXPRESSION AS A POSSIBLE PREDICTIVE BIOMARKER OF 2-CHLORO-2'-DEOXYADENOSINE CLINICAL ACTIVITY
C. Rabascio, D. Laszlo, L. Saronni, V. Raia, F. Bertolini, P. Antoniotti, A. Pinto, F. Frigeri, A. Fabbri, L. Rigacci, A. Billio, G. Martinelli (European Institute of Oncology, Milan, Italy)
 
0630 LYMPHOMA CELLS MICRODISSECTED FROM PRIMARY SPLENIC LOW GRADE NON-HODGKINS LYMPHOMA BUT NOT NORMAL SPLENIC CELLS CONTAIN HCV GENOME
A. de De Renzo, B. De Angelis, F. Perna, G. Ciancia, C. Quintarelli, M. Picardi, R. Ciancia, M. Persico, B. Rotoli, F. Pane (University of Naples, Naples, Italy)
 

ACUTE MYELOID LEUKEMIA III

 
0631 APPLICATION OF EXTENDED COX PROPORTIONAL HAZARD MODELS ON THE DATA SETS OF THE ORIGINAL DATA BASED META-ANALYSIS ON PATIENTS 18 TO 60 YEARS OF AGE WITH CORE-BINDING-FACTOR ACUTE MYELOID LEUKEMIA OF THE GERMAN AML-INTERGROUP
R.F. Schlenk, R. Krahl, C. Sauerland, T. Büchner, S. Soucek, M. Schaich, J. Krauter, A. Ganser, I. Schäfer, G. Ehninger, K. Döhner, H. Döhner, A. Benner (University of Ulm, Ulm, Germany)
 
0632 ALL-TRANS RETINOIC ACID AND GEMTUZUMAB OZOGAMICIN AS ADJUNCT TO SALVAGE THERAPY IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF CONSECUTIVE PHASE II STUDIES OF THE AMLSG
R.F. Schlenk, K. Döhner, M. Kerz, B. Heydrich, A. Glasmacher, H. Pralle, K. Götze, E. Koller, W. Fiedler, D. Haase, M. Theobald, D. Nachbaur, A. Ganser, H. Döhner (University of Ulm, Ulm, Germany)
 
0633 GENETIC CHARACTERIZATION OF PATIENTS WITH AML-M2. THE JAK2 V617F ACTIVATING MUTATION IS FREQUENTLY FOUND IN CASES WITH NORMAL KARYOTYPE
A. Conchillo, I. Vazquez, C. Vicente, N. Marcotegui, G. Rivell, C. Carranza, E. Bandres, X. Agirre, M.J. Larrayoz, M.J. Calasanz, I. Lahortiga, M.D. Odero (CIMA, University of Navarra, Pamplona, Spain)
 
0634 PREFERENTIAL METHYLATION OF WNT INHIBITORY FACTOR-1 IN ACUTE PROMYELOCYTIC LEUKAEMIA: AN INDEPENDENT POOR PROGNOSTIC FACTOR
C.S. Chim, W.W. Chan, Y.L. Kwong (Queen Mary Hospital, Hong Kong, Hongkong (China))
 
0635 IMPLICATIONS OF REAL TIME FLIP GENE EXPRESSIONS ON THE CLINICAL OUTCOME IN ADULT PATIENTS WITH AML
H.J. Kim, Y. Choi, H.Y. Jeong, W.S. Min, J.W. Lee, C.C. Kim (CHSCTC, Catholic Univ. of Korea, Seoul, South-Korea)
 
0636 EXPRESSION OF THE BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC (BAALC) GENE IN ACUTE MYELOID LEUKEMIA
P Bernasconi, S. Calatroni, B. Rocca, M. Boni, R. Zappatore, P.M. Cavigliano, I. Giardini, I. Dambruoso, M. Lunghi, M. Caresana, C. Astori, C. Castagnola, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0637 THE OUTCOME OF POSTREMISSION TREATMENT FOR AML WITH FAVORABLE CYTOGENETICS IN FIRST REMISSION
H.-J. Shin, J.S. Chung, Y.J. Choi, G.J. Cho, H.-J. Kim, Y.-K. Kim, D.-H. Yang, S.K. Sohn, J.G. Kim (Pusan National University Hospital, Busan, South-Korea)
 
0638 ARE FLT3 ITD AND D835 MUTATIONS SUFFICIENT INDICATORS FOR ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA? AN ANALYSIS OF PATIENTS FROM THE CZECH ACUTE LEUKEMIA CLINICAL REGISTER (ALERT)
M. Doubek, J. Muzik, T. Szotkowski, V. Koza, P. Cetkovsky, T. Kozak, J. Voglova, L. Dusek, K. Indrak (University Hospital, Brno, Czech Republic)
 
0633 OPTIMISATION OF A 48HOUR IN VITRO CHEMOSENSITIVITY ASSAY FOR CD34+CD38-CD123+ LEUKAEMIC STEM AND PROGENITOR CELLS
M. Pallis, U. Mony, N. Russel, M. Pallis (Nottingham City Hospital, Nottingham, United Kingdom)
 
0640 EXPRESSION OF P73 AND P53 PROTEINS IN LEUKEMIC CELLS AND SURVIVAL OF ACUTE MYELOID LEUKEMIA PATIENTS
A. Pluta, P. Smolewski, B. Cebula, K. Jamroziak, A. Wierzbowska, A. Wrzesien-Kus, T. Robak (Medical University of Lodz, Lodz, Poland)
 
0641 GENE EXPRESSION PROFILE OF ACUTE MYELOID LEUKEMIA (AML) WITH MULTILINEAGE DYSPLASIA CONFIRMS ITS BIOLOGICAL HETEROGENEITY
M. Rozman, J. Esteve, M. Camos, S.G. Kalko, J.L.l. Aguilar, M. Torrebadell, D. Costa, A. Carrio, E. Montserrat, E. Campo (Hospital Clinic, Barcelona, Spain)
 
0642 THE USE OF BIOCHEMICAL MARKERS, ECHOCARDIOGRAPHY AND ELECTROCARDIOGRAPHY IN THE ASSESSMENT OF CARDIOTOXICITY IN PATIENTS TREATED FOR ACUTE LEUKEMIA
J.M. Horacek, R. Pudil, M. Tichy, L. Jebavy, P. Zak, A. Strasova, L. Slovacek, M. Blazek, J. Maly (Faculty Hospital, Charles University, Hradec Kralove, Czech Republic)
 
0643 THE GROWTH AND SURVIVAL OF AML CELLS WITH T(8;21) ARE DEPENDENT ON VEGF / VEGF RECEPTOR TYPE2 AND PHOSPHORYLATION OF AKT
H. Miwa, N. Imai, M. Shikami, A. Hiramatsu, M. Watarai, E. Tajima, H. Yamamoto, K. Suganuma, A. Satoh, M. Itoh, A. Imamura, H. Mihara, M. Nitta (Aichi Medical University, Nagakute, Japan)
 
0644 A NOVEL MUTATION IN THE EXON 11 OF NUCLEOPHOSMIN (NPM1) GENE LEADS TO A TRUNCATED FORM OF THE PROTEIN LACKING THE C-TERMINAL NES-MOTIF
E. Albiero, D. Madeo, I. Giaretta, C. Borghero, C. Visco, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
 
0645 EXTRAMEDULLARY INFILTRATES OF AML: BIOLOGICAL AND CLINICAL FEATURES IN A SINGLE CENTRE EXPERIENCE
P. Carluccio, D. Pastore, F. Albano, A. Mestice, S. Sibilla, M. Giannoccaro, A. Pannunzio, M. Leo, A.M. Mazzone, M. Casanova, M. Santodirocco, V. Liso, G. Specchia (Hematology, Bari, Italy)
 
0646 SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS OF TRANSCRIPTION FACTOR GENES IN ACUTE MYELOID LEUKEMIA
Y.K. Kim, I.K. Lee, K.S. Park, H.N. Kim, J.S. Ahn, D.H. Yang, S.H. Cho, M.R. Park, I.J. Chung, H.J. Kim (Chonnam Natl, Univ. Hwasun Hospital, HD, Jeollanamdo, South-Korea)
 
0647 CHARACTERIZATION OF AML-M0: A SEARCH FOR TUMOR SUPPRESSOR GENES AND ONCOGENES
F.P.G. Silva, I. Almeida, M. van Velzen, A. Lind, B. Morolli, F. de Zwart, Y. Ariyurek, S. White, H. Wessels, P. Valk, W.R. Sperr, W.A.F. Marijt, H.C. Kluin- Nelemans, W. Ludwig, M. Giphart-Gassler (Leiden University Medical Centre, Leiden, The Netherlands)
 
0648 STEM CELL TRANSPLANTATION IMPROVES OUTCOME IN YOUNGER ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE MINIMAL RESIDUAL DISEASE AT THE END OF POST-REMISSION CHEMOTHERAPY
E. Laane (Karolinska Institute, Stockholm, Sweden)
 
0649 K313 DUP CEBPA MUTATION IS A RECURRENT MOLECULAR LESION IN DE NOVO ACUTE MYELOID LEUKEMIA (AML)
M.J. Carnicer, E. Serrano, A. Lasa, M. Gimbert, S. Brunet, A. Aventin, J. Sierra, J.F. Nomdedeu (Hospital, Barcelona, Spain)
 

ACUTE LYMPHOBLASTIC LEUKEMIA

 
0650 SPECIFIC INTENSIVE CHEMOTHERAPY PLUS RITUXIMAB FOR BURKITT'S LYMPHOMA OR LEUKEMIA IN HIV-POSITIVE AND NEGATIVE ADULT PATIENTS
A.O. Oriol, J.M. Ribera, J. Bergua, E. Giménez-Mesa, C. Grande, J. Esteve, S. Brunet, M.J. Moreno, L. Escoda, J.M. Hernández-Rivas, E. Feliu (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)
 
0651 MINIMAL RESIDUAL DISEASE ANALYSIS IN NON-MRD BASED TREATMENT PROTOCOL FOR CHILDHOOD ALL: LOW RISK FEATURES TOGETHER WITH FAST MORPHOLOGICAL RESPONSE FAIL TO IDENTIFY SLOW-RESPONDERS WITHIN THE ALL IC-BFM 2002 STANDARD RISK GROUP
E. Fronkova, S. Avigad, K.W. Chik, L. Castillo, S. Manor, L. Reznickova, E. Mejstrikova, M. Schrappe, V. Conter, S. Izraeli, B. Stark, J. Stary, J. Trka (2nd Medical School, Charles University, Prague, Czech Republic)
 
0652 MULTIVARIATE ANALYSIS INCLUDING MTHFR GENOTYPES IN A COHORT OF ALL PATIENTS
G. Farina, G. Reddiconto, M. Palladino, A. Fiorini, P. Chiusolo, A. Mannocci, G. La Torre, L. Fianchi, S. Giammarco, L. Laurenti, S. Sica, G. Leone (Universitŕ Cattolica del Sacro Cuore, Rome, Italy)
 
0653 DASATINIB (D) IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN LYMPHOID BLAST CRISIS (LB-CML) OR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS IMATINIB (IM)-RESISTANT (IM-R) OR INTOLERANT (IM-I): THE CA180015 'START-L' STUDY
O. Ottmann, G. Martinelli, H. Dombret, B. Simonsson, G. Saglio, A. Gollerkeri, A. Apanovitch, P. Erben, S. Coutre, H. Kantarjian (Johann Wolfgang Goethe Universitaet, Frankfurt, Germany)
 
0654 CRYPTIC KARYOTYPE DEFECTS ARE DISCOVERED BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (I-FISH) IN CHROMOSOMALLY NORMAL ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
P. Bernasconi, P.M. Cavigliano, I. Giardini, I. Dambruoso, M. Boni, R. Zappatore, S. Calatroni, B. Rocca, M. Lunghi, M. Caresana, C. Astori, C. Castagnola, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0655 WILMS' TUMOR GENE 1 (WT1) EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
L. Boublikova, M. Kalinova, J. Ryan, F. Quinn, A. O'Marcaigh, O. Smith, P. Browne, J. Stary, S.R. McCann, J. Trka, M. Lawler (Institute of Molecular Medicine, Dublin, Ireland)
 
0656 CELL BIOLOGICAL FEATURES OF BLASTS PERSISTING AT DAY 8 OF INDUCTION THERAPY IN CHILDHOOD PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
P. Rhein, S. Scheid, R. Ratei, C. Hagemeier, K. Seeger, R. Kirschner-Schwabe, M. Schrappe, R. Spang, W.D. Ludwig, L. Karawajew (Robert-Rossle-Clinic, HELIOS Klinikum, Berlin, Germany)
 
0657 MINIMAL RESIDUAL DISEASE MONITORING OF BCR-ABL POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA USING QUANTITATIVE REAL-TIME PCR: PRELIMINARY RESULTS FROM THE MRC-UKALLXII TRIAL
G. Gerrard, W. Mitchell, B. Patel, A. Goldstone, L. Foroni (Royal Free & UCMS, London, United Kingdom)
 
0658 SHOULD HYPERCVAD/METHOTREXATE-CYTARABINE BE CONSIDERED A STANDARD TREATMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA? A BRAZILIAN EXPERIENCE
M. Avanzi, L. Dalmazzo, R. Schaffel, M. Favarin, R.D. Portugal, R. Vilar, M.I. Ayrosa, L. Oliveira, L.L. Figueiredo, M.C. Pintao, E.M. Rego, M.A. Zanichelli, N. Spector, B.P. Simoes (Medical School Ribeirao Preto, Ribeirao Preto, Brazil)
 
0659 IMATINIB COMBINED TO INDUCTION OR CONSOLIDATION CHEMOTHERAPY IN YOUNGER PATIENTS WITH DE NOVO PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA - RESULTS OF THE GRAAPH-2003 STUDY
A. De Labarthe, P. Rousselot, F. Huguet-Rigal, E. Delabesse, F. Witz, C. Pautas, D. Rea, J.M. Cayuela, A. Delannoy, O. Reman, A. Pigneux, E. MacIntyre, J.P. Vernant, X. Thomas, N. Ifrah, H. Dombret (Hôpital Saint-Louis, Paris, France)
 
0660 ROLE OF P21 IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: METHYLATION STATUS AND PROTEIN EXPRESSION
M.T. Petrucci, F. De Cave, C. Gregorj, M.R. Ricciardi, M.C. Scerpa, G. Specchia, A. Cupri, F. Ferrara, F. Mondello, C. Rinaldi, G. Fioritoni, N. Cascavilla, E. Miraglia, M. Vignetti, R. Foŕ, A. Tafuri, M.T. Petrucci (Division of Hematology, Rome, Italy)
 
0661 PROGNOSTIC VALUE OF HOX11L2/TLX3 AND TAL1/SCL EXPRESSION IN CHILDHOOD T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL): RESULTS OF THE FRALLE 93 PROTOCOL
P Ballerini, J.M. Cayuela, V. Asnafi, P. Levy, M.F. Auclerc, S. Fasola, Y. Perel, V. Gandemer, G. Michel, T. Leblanc, E.A. Macintyre, A. Hagemeijer, G. Leverger, A. Baruchel, J. Landman-Parker (Hôpital Armand Trousseau, Paris, France)
 
0662 QUANTIFICATION OF DRUG INDUCED CASPASE ACTIVATION IN PRIMARY LEUKEMIA CELLS IN VITRO AND IN VIVO BY FLOW CYTOMETRY
S.M. Eckhoff, L.H. Meyer, K.M. Debatin, K. Stahnke (University of Ulm, Ulm, Germany)
 
0663 RESULTS OF THE PETHEMA ALL-96 TRIAL IN ELDERLY PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
B. Xicoy, J.M. Ribera, J.M. Sancho, A. Oriol, M. Tormo, E. Del Potro, G. Deben, E. Abella, C. Bethencourt, X. Ortin, S. Brunet, F. Ortega-Rivas, A. Novo, R. Lopez, J.M. Hernandez-Rivas, M.A. Sanz (Pethema Group, Badalona, Spain)
 
0664 MATURE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA : A REPORT OF 31 PEDIATRIC CASES
S. Girard, C. Mazellier, M.P. Pages, V. Mialou, F. Mazingue, D. Plantaz, C. Behar, A. Ferster, L. Lutz, Y. Benoit, Y. Bertrand (Hospices Civils de Lyon, Lyon Cedex 05, France)
 
0665 SMALL 9P21-DELETIONS DETECTED BY MATRIX-CGH IN PATIENTS WITH ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) INDICATE POOR PROGNOSIS
M.S. Schmid, C. Schwänen, S. Ruf, H. Döhner, S. Wessendorf (University hospital of Ulm, Ulm, Germany)
 
0666 EFFICACY AND TOXICITY OF IDA/NOVA-FLAG REGIMEN AS SALVAGE TREATMENT FOR PATIENTS WITH ACUTE LEUKEMIA (AL). FIVE-YEAR-EXPERIENCE OF A SINGLE INSTITUTE
M. Dimou, E. Kyriakou, S. Chrysochoou, C. Zouvelou, G. Georgiou, P. Greka, D. Doufexis, M.C. Kyrtsonis, P. Panayiotidis (Laikon General Hospital, Athens, Greece)
 
0667 EFFECT OF INTENSIVE CHEMOTHERAPY ON INNATE IMMUNITY IN CHILDREN WITH ACUTE LEUKEMIA AND NON-HODGKIN LYMPHOMA
M. Jarosz, J. Mysliwska, A. Balcerska (Medical University of Gdansk, Poland, Gdansk, Poland)
 
0668 RISK-ADAPTED THERAPY FOR ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
N. Cascavilla, L. Melillo, C. Bodenizza, A.M. Carella, M. Dell'Olio, A.P. Falcone, M.M. Greco, A. La Sala, P. Musto, M. Nobile, S. Mantuano, E. Merla, M.M. Minervini, G. Sanpaolo, P.R. Scalzulli (IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy)
 
0669 PROGNOSTIC RELEVANCE OF THE IMMUNOPHENOTYPE IN ADULTS AND CHILDREN WITH T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
N. Cascavilla, L. Melillo, A.M. Carella, G. D'Arena, M. Dell'Olio, R. De Santis, A.P. Falcone, S. Mantuano, E. Merla, L. Miglionico, M.M. Minervini, P. Musto, G. Perla, G. Sanpaolo, P.R. Scalzulli, S. Ladogana (IRCCS "CSS" Hospital, San Giovanni Rotondo, Italy)
 
0670 BONE MINERAL DENSITY IN SURVIVORS OF ACUTE LYMPHOBLASTIC LEUKEMIA DURING CHILDHOOD
A. Gunes Meral, E. Can, B. Baytan, U. Gunay (Uludag university, Bursa, Turkey)
 
0671 LONG TERM OUTCOME OF ALLOGENEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA - COLLABORATIVE ANALYSIS FROM THREE CENTERS
A. Czyz, J.M. Zaucha, L. Gil, B. Nasilowska, W. Knopinska-Posluszny, M. Bieniaszewska, D. Dytfeld, A. Lojko, B. Marianska, A. Hellman, M. Komarnicki (University of Medical Sciences, Poznan, Poland)
 

CHRONIC MYELOID LEUKEMIA III

 
0672 CYTOGENETIC AND MOLECULAR MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CML IN CHRONIC PHASE ON IMATINIB MESYLATE THERAPY- THE SINGAPORE GENERAL HOSPITAL EXPERIENCE
G.F. How, C.T.H. Chuah, L.T. Tan, L.C. Lim (Singapore General Hospital, Singapore, Singapore)
 
0673 KINETICS OF TWO CO-EXISTING MUTATIONS IN THE BCR-ABL KINASE DOMAIN (KD) IN FOUR CML PATIENTS
J.S.K. Khorashad, S. Khorashad, C. Marin, M. Goldman, F. Apperley, S. Kaeda (Imperial College, London, United Kingdom)
 
0674 PROGNOSTIC SIGNIFICANCE OF THE LEVEL OF RESIDUAL DISEASE AFTER 12 MONTHS IMATINIB BASED THERAPY: THE GERMAN CML-STUDY IV
P. Erben, M.C. Mueller, L. Sadikaj, M. Kripp, C. Schneider, T. Lorenz, T. Schenk, T. Ernst, S. Lauber, J. Kruth, S. Saußele, T. Lahaye, U. Berger, R Hehlmann, A. Hochhaus (III. Med. Klinik Mannheim Uni Heidelberg, Mannheim, Germany)
 
0675 MUTATION ANALYSIS OF THE KINASE DOMAIN OF THE BCR/ABL FUSION GENE IN CHRONIC MYELOGENOUS LEUKAEMIA
Y. Wei, R. Hezaveh, B. Olsson, A. Ricksten, L. Palmqvist, D. Stockelberg, H. Wadenvik (Dept of Internal Medicine, Qilu Hospital, Jinan, China)
 
0676 BENEFIT OF IMATINIB AT 600 MG/DAY FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN ACCELERATED PHASE : A RETROSPECTIVE STUDY OF 44 PATIENTS
K. Bouabdallah, C. Foucaud, M.P. Fort, G. Marit, F.X. Mahon (Service des Maladies du Sang, Pessac, France)
 
0677 PRAME AS A SECONDARY TARGET FOR BCR-ABL-POSITIVE LEUKEMIAS
D.D. Carvalho, R. Proto-Siqueira, J.M.G. Leroy, W.O. Pereira, M.A. Zanichelli, M.D. Colassantti, D. Camanho, D.L.C. Alves, M.A. Zago, F.A. Castro, G.P. Amarante-Mendes (ICB-USP, Săo Paulo, Brazil)
 
0678 GENETIC CHARACTERIZATION OF 203 DE NOVO CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN THE PORTUGUESE POPULATION
F.T. Torres, A. Ivanova, M. Pereira, R. Lemos, C. Ventura, P. Cardoso, I. Miguel, A. Sousa, N. Morais, P. Rendeiro, P. Tavares, A.R. Fernandes (CGC, Porto, Portugal)
 
0679 GENE EXPRESSION PROFILING IN CML PATIENTS RESISTANT TO TREATMENT - SPECIFIC PROFILES IN NON-RESPONDERS WITH LOW BCR-ABL TRANSCRIPT LEVELS
K. Fis? er, D. Moucková, E. Otáhalová, J. Moravcová (Inst. of Hematol. and Blood Transf., Praha, Czech Republic)
 
0680 THE EXPRESSION OF PROTO-ONCOGENES IN THE COURSE OF CHRONIC MYELOID LEUKEMIA
A. Vidovic, G. Jankovic, M. Colovic, D. Tomin, M. Perunicic, I. Djunic, D. Antic, J. Bila, M. Bakrac, O. Markovic, V. Cemerikic, D. Boskovic (Institute of Hematology, Belgrade, Serbia and Montenegro)
 
0681 P190 BCR-ABL CHRONIC MYELOID LEUKEMIA PARTLY RESEMBLING CHRONIC MYELOMONOCYTIC LEUKEMIA IN A YOUNG PATIENT TREATED WITH IMATINIB
J. Diamond, H. Alaiz, R. Domingues, M. Gomes Silva, M.J. Frade, A. Parreira (Portuguese Institute of Oncology - IPO, Lisbon, Portugal)
 
0682 ANGIOGENIC ACTIVATORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: EFFECT OF TREATMENT WITH IMATINIB MESYLATE
L. Smolej, J. Voglova, C. Andrys (Charles Univ.Hospital and Medical School,Hradec Kralove, Czech Republic)
 
0683 THE E19A2 BCR-ABL BREAKPOINT: MORE FREQUENT THAN OTHER ATYPICAL BCR-ABL VARIANTS IN CHRONIC MYELOGENOUS LEUKEMIA (CML)?
I. Iacobucci, G. Martinelli, G. Rosti, F. Castagnetti, M. Amabile, A. Poerio, S. Soverini, S. Colarossi, A. Gnani, S. Amadori, E. Abruzzese, D. Cilloni, G. Saglio, M. Baccarani, F. Pane (University of Bologna, Bologna, Italy)
 
0684 GENE EXPRESSION PROFILE OF PATIENTS INNATELY RESISTANT TO IMATINIB MESYLATE
A. Santoro, G. Cammarata, M. La Rosa, D. Turri, S. Tringali, A. Marfia, C. Agueli, V. Rizzo, R. Giustolisi, S. Mirto (Cervello Hospital, Palermo, Italy)
 
0685 PROGNOSTIC SIGNIFICANCE OF WT1 GENE EXPRESSION IN CHRONIC MYELOGENOUS LEUKEMIA (CML) TREATED WITH IMATINIB
M.H. Hardling, Y. Wei, K. Ekeland-Sjöberg, D. Stockelberg, A. Ricksten, H. Wadenvik (Hematology Section, Goteborg, Sweden)
 
0686 MONITORING OF MOLECULAR RESPONSE TO STI OR STIINFALPHA OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
A.M. Liberati, M. Schippa, L. Falchi, G. Desantis, A. Rauco, A. Bassetti, E. Donti, M. Fava, E. Gottardi, G. Saglio (Medicina Interna e Scienze Oncologiche, Perugia, Italy)
 
0687 PROLONGED MOLECULAR REMISSION IN A LATE CHRONIC PHASE CML PATIENT AFTER DISCONTINUATION OF IMATINIB TREATMENT
G. Rege-Cambrin, C. Fava, G. Mattioli, E. Giugliano, E. Gottardi, M. Fava, S. Ulisciani, P. Scaravaglio, G. Saglio (S. Luigi Hospital, Orbassano, Torino, Italy)
 
0688 CHRONIC MYELOID LEUKEMIA AFTER TREATMENT WITH 131-I FOR THYROID NEOPLASMS: TWO NEW CASES AND REVIEW OF THE LITERATURE
J.A. Ruano, G. González-Brito, H. Alvarez-Arguelles, J.M. Raya, B.J. González, M.T. Hernández-García, M.J. Rodríguez-Salazar, R.F. Rodríguez-Sánchez, M.L. Brito, L. Hernández-Nieto (Hospital Universitario de Canarias, La Laguna - Tenerife, Spain)
 
0689 FOLLOW-UP OF CML PATIENTS WITH CLONAL CYTOGENETIC ABNORMALITIES IN PH NEGATIVE CELLS DURING TREATMENT WITH IMATINIB
A.C. Oliveira, M. Arnan, E. Alonso, B. Espinet, C. Garcia, C. Boqué (Institut Catala d'Oncologia, Barcelona, Spain)
 

NON-HODGKIN'S LYMPHOMA - CLINICAL III

 
0690 THE OUTCOME OF 71 PATIENTS WITH PRIMARY MEDIASTINAL LARGE BCELL LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE
L. Mazurok, O. Kolomeytsev, T. Kondrateva, N. Probatova, A. Pavlovskaya, E. Sholohova, O. Trofimova, G. Tumyan, I. Poddubnaya, N. Tupitsyn, D. Osmanov (N.N.Blokhin Russian Cancer Research Cent, Moscow, Russian Federation)
 
0691 DIAGNOSTIC SENSITIVITY OF PET/CT IN PATIENTS WITH EXTRANODAL MARGINAL ZONE (MALT) LYMPHOMA
C. Perry, Y. Harishanu, U. Metser, O. Bairey, E. Naparstek, E. Even Sapir, A. Polliack (Tel Aviv Sourasky Medical Center, Tel Aviv, Israel)
 
0692 BENIGN STRICTURES FOLLOWING TREATMENT FOR PRIMARY GASTROINTESTINAL NON-HODGKIN'S LYMPHOMA: CASE SERIES
J. Kerr, M. Turner, M. Ashton-key, G.M. Mead, P.W. Johnson (Cancer Research UK/, Southampton, United Kingdom)
 
0693 ACTIVITY OF RITUXIMAB PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN/MITOXANTRONE, VINCRISTINE AND PREDISONE (R-CHOP/R-CNOP) IN PATIENTS WITH RELAPSED MALT-LYMPHOMA
M. Raderer, S. Woehrer, B. Streubel, J. Drach, U. Jaeger, K. Turetschek, M. Troch, A Puespoek, C. Zielinski, A. Chott (University of Vienna, Vienna, Austria)
 
0694 INFLUENCE OF RITUXIMAB, CYCLOPHOSPHAMID, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) ON SEROLOGIC PARAMETERS AND CLINICAL COURSE IN LYMPHOMA PATIENTS WITH AUTOIMMUNE DISEASES
M. Troch, J. Zwerina, G. Schett, C. Skrabs, A. Gaiger, U. Jaeger, C.C. Zielinski, M. Raderer, S. Woehrer (Medical University of Vienna, Wien, Austria)
 
0695 PET/CT DIAGNOSTIC ACCURACY IN LYMPHOMA
D. Hernandez-Maraver, B. Rodriguez Vigil, J. Coya, R. De Paz, I. Pinilla, M. Coronado, M. Canales, M.J. Sanjurjo, L.M. Martin Curto, N. Gomez-Leon, F. Hernandez Navarro (Hospital La Paz, Madrid, Spain)
 
0696 EFFICACY AND SAFETY OF DEPOCYTE(R) (LIPOSOMAL CYTARABINE) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT FROM NON-HODGKIN'S LYMPHOMA: A REPORT ON 23 PATIENTS TREATED IN SPAIN
A. García-Marco, B. Navarro, E. Sanz, L. Palomera, F.J. Capote, A. Fernández de Sevilla, E. Sánchez, A. Cantalapiedra, R. Pérez, J. Casal, J.D. Mediavilla, F.R. García, Y. Martín, C. Panizo, A. Alvarez, T. García, G. Pérez (Hospital Universitario Puerta de Hierro, Madrid, Spain)
 
0697 LACK OF HUMORAL RESPONSE TO ACUTE EBV INFECTION MAY IDENTIFY PATIENTS WITH FULMINANT EBV-ASSOCIATED NK/T-CELL LYMPHOPROLIFERATIVE DISORDER
C.L. Tan, L.P. Koh, B.C. Koh, S.M. Loh, T.H. Chuah, Y.T. Goh (Singapore General Hospital, Singapore, Singapore)
 
0698 DOSE-DENSE CHOP (CHOP-14) PLUS RITUXIMAB FOR NEWLY DIAGNOSED AGGRESSIVE B CELL LYMPHOMA. A PROSPECTIVE MULTICENTRIC STUDY. GRUPO PARA EL ESTUDIO DE HEMOPATIAS MALIGNAS - GALICIA
E. Lavilla, M. Perez Encinas, E. Romero, A. Simiele, E. Gómez Torreiro, M.J. Plaza, J. Arias (Hospital Xeral, Lugo, Spain)
 
0699 RITUXIMAB AND ESHAP PLUS G-CSF AS AN EFFECTIVE PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION REGIMEN IN PRETREATED B-CELL NON-HODGKIN'S LYMPHOMA: A PRELIMINARY REPORT OF COMPARISON WITH ESHAP PLUS G-CSF
C. Suh, S. Kim, Y.H. Cho (Asan Medical Center, Seoul, South-Korea)
 
0700 THE OCCURRENCE OF CNS RELAPSES IN HIGH-RISK AGGRESSIVE LYMPHOMA PATIENS TREATED WITH INTENSIFIED INDUCTION AND HIGH-DOSE CONSOLIDATION PROTOCOLS OF THE CZECH LYMPHOMA STUDY GROUP
I. Vasova, R. Pytlik, D. Belada, M. Jankovska, K. Kubackova, J. Pirnos, M. Matuska, I. Bolomska, M. Trneny, M. Hamouzova (Masaryk University Hospital, Brno, Czech Republic)
 
0701 BURKITT AND NON-BURKITT TYPES OF CHIDHOOD B-CELL LYMPHOMAS (B- NHL) - COMPARISON OF TREATMENT RESULTS. A REPORT OF POLISH PAEDIATRIC LEUKEMIA/ LYMPHOMA STUDY GROUP ( PPLLSG)
S.E. Sowinska, K.B. Kazanowska, W.G. Wrobel, J.M. Jelen, M.J. Maldyk, B.H. Bubala, D.A. Dluzniewska, K.L. Kapuscinska, K.A. Koltan, P.S. Popadiuk, R.K. Roslan, S.B. Sopylo, S.J. Stefaniak, SK Stefanska (Wroclaw Medical University,Poland, Wroclaw, Poland)
 
0702 HAEMATOLOGICAL AND EXTRAHAEMATOLOGICAL MALIGNANCIES AFTER AUTOLOGOUS TRANSPLANTION FOR LYMPHOPROLIFERATIVE DISEASES
M. Tarnani, L. Laurenti, P. Chiusolo, M. Garzia, L. De Padua, P. Piccioni, G. Reddiconto, M. Zollino, L. Pagano, F. Sorŕ, S. De Vita, S. Sica, G. Leone (Istituto di ematologia UCSC-Roma, Roma, Italy)
 
0703 THE COMPARISON OF PERIPHERAL T-CELL LYMPHOMA WITH DIFFUSE LARGE B-CELL LYMPHOMA WHEN TREATED WITH SAME FIRST LINE CHOP CHEMOTHERAPY
H. Kim, C. Seo, S. Kim, J.S. Lee, W.K. Kim, Y.D. Joo, W.S. Lee, J.H. Park (Ulsan University Hospital, Ulsan, South-Korea)
 
0704 RITUXIMAB-CHOP (R-CHOP) AND RADIOTHERAPY (RT) FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): AN UPDATE
T.P. Vassilakopoulos, M.K. Angelopoulou, Z. Galani, S. Sachanas, A. Katsigiannis, E. Vrakidou, N. Constantinou, M.N. Dimopoulou, S.I. Kokoris, E. Michali, E.M. Dimitriadou, M.P. Siakantaris, P. Panayiotidis, P. Roussou, G.A. Pangalis (University of Athens, Athens, Greece)
 
0705 TREATMENT STRATIFICATION ACCORDING TO EARLY RESPONSE TO MEGA-CHOP, BASED ON CT AND GALLIUM 67 SCAN (G67S) WITH OR WITHOUT IFE SALVAGE THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN PATIENT WITH POOR PROGNOSIS AGGRESSIVE LYMPHOMA
E. Conde, R. Arranz, J. Rodriguez, C. Grande, M. Gandarillas, J.L. Bello, C. Albo, M.L. Gutierrez, S. Garzón, M.T. Hernández, J.A. García Vela, P. Fernández, M.L. Amigo, D. Caballero (Hospital Valdecilla, Santander, Spain)
 
0706 PRELIMINARY RESULTS FROM A PHASE II STUDY OF LENALIDOMIDE MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
H. Wiernik, I.S. Lossos, G. Justice, J.M. Tuscano, J.B. Zeldis, K. Takeshita, D. Pietronigro, T. Habermann (New York Medical College, Bronx, Ny, USA)
 
0707 RITUXIMAB SIGNIFICANLY IMPROVES THE OUTCOME OF YOUNG POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA - ON BEHALF OF CZECH LYMPHOMA STUDY GROUP
M. Trneny, D. Belada, I. Vasova, R. Pytlik, T. Kozak, A. Sykorova, K. Kubackova, J. Pirnos, I. Bolomska, M. Hamouzova (Charles Univ General Hospital, Praha, Czech Republic)
 
0708 WHATS THE SIGNIFICANCE OF FDG-PET/CT SCAN AT DIAGNOSIS OF NON HODGKIN LYMPHOMAS?
R. Sancetta, M. Gregianin, F. Dei Rossi, E. Cracco, P. Pregno, U. Vitolo, L. Rigacci, F. Merli, T. Chisesi (Ospedale Civile "Umberto I", Venezia-mestre, Italy)
 
0709 EXTRA-NODAL NON-HODGKIN LYMPHOMAS AT A COMPREHENSIVE CANCER CENTRE IN PORTUGAL
N. Sousa, T. Jaraquemada, M. Juan, I. Oliveira, A. Martins, M. Mariz, L. Viterbo, H. Marques, P. Teixeira, M. Marques (Instituto Portuguęs de Oncologia-Porto, Porto, Portugal)
 

NON-HODGKIN'S LYMPHOMA - CLINICAL IV

 
0710 INTERLEUKIN-8 AND INTERLEUKIN-10 LEVELS IN DIFFUSE LARGE BCELL LYMPHOMA: CORRELATION WITH INTERNATIONAL PROGNOSTIC INDEX AND OUTCOME
A. Duletic-Nacinovic, S. Dvornik, I. Host, J. Kalcic, B. Krajnovic, D. Petranovic, M. Sever-Prebilic, T. Valkovic, N. Jonjic, K. Lucin, S. Stifter (Clinical Hospital Centre Rijeka, Rijeka, Croatia)
 
0711 ANTI-LEUKEMIC AND ANTI-ANGIOGENESIS EFFICACY OF ARSENIC TRIOXIDE IN NEW CASES OF ACUTE PROMYELOCYTIC LEUKEMIA
Z. Sanaat (Tabriz University of Medical Science, Tabriz, Iran)
 
0712 SALVAGE TREATMENT WITH HIGH-DOSE THERAPY AND PSCT IN HIGH GRADE NHL - FROM THE GISL (GRUPPO ITALIANO STUDIO LINFOMI)
P. Mazza, M.R. Specchia, S. Luminari, L. Marcheselli, M. Dell'Olio, P. Gobbi, C. Stelitano, M. Federico (Oncoematologia, P.O. "S.G. Moscati", Taranto, Italy)
 
0713 THE EFFICACY OF RITUXIMAB PLUS IFOSFAMIDE SECOND LINE APPROACH IN RELAPSED/ REFRACTORY NON HODGKIN LYMPHOMA (NHL)
V.B. Bongarzoni, A.C. Chierichini, P.A.B. Anticoli Borza, B. Anaclerico, M. Bartolini, S. Fenu, M. Cedrone, M.V. Vittori, M.P. Persiani, B.R. Ronci, M.C. Cantonetti, M.C.P. Petti, L. Annino (Azienda Ospedaliera "S. Giovanni", Rome, Italy)
 
0714 SPLENIC MARGINAL ZONE LYMPHOMA: A CLINICOPATHOLOGICAL STUDY IN 16 PATIENTS
J.M. Raya, J.A. Ruano, J.M. Bosch, E. Golvano, T. Molero, A. Lemes, J. Cuesta, J.M. Calvo, E. Carreter, M.L. Brito, M.T. Hernández-García, L. Hernández-Nieto (Hospital Universitario de Canarias, La Laguna - Tenerife, Spain)
 
0715 IS DOUBLE-BALLOON ENDOSCOPY USEFUL AND NECESSARY FOR THE EVALUATION OF SMALL INTESTINE INVASION IN PATIENTS WITH NHL?
T.K. Kato (Gifu University School of Medicine, Gifu-city, Japan)
 
0716 NODAL VS. PRIMARY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMAS: A COMPARISON OF PRESENTING FEATURES, RESPONSE TO TREATMENT AND OUTCOME
D. Mihou, P. Konstantinidou, Fr. Patakiouta, D. Markala, A. Banti, E. Verrou, N. Constantinou ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0717 THE LATE CARDIOTOXICITY OF DOXORUBICIN CONTAINING REGIMENS IN THE TREATMENT OF MALIGNANT LYMPHOMAS
I. Vasova, L. Elbl, M. Navratil, I. Tomaskova, Z. Kral, D. Salek, F. Jedlicka, L. Smardova, J. Mayer (Masaryk University Hospital, Brno, Czech Republic)
 
0718 PROGNOSTIC SIGNIFICANCE OF GAMMA-DELTA T CELL RECEPTOR ( TCR GD ) EXPRESSION IN BONE MARROW LYMPHOCYTE POPULATION OF LYMPHOMA MALIGNUM ( NHL) PATIENTS
S.E. Sowinska, U.Z.L. Usnarska-Zubkiewicz, K.K. Kuliczkowski (Wroclaw Medical University,Poland, Wroclaw, Poland)
 
0719 EXPRESSION OF A FEW T CELL ANTIGENS AND EARLY T ORIGIN OF T-ALL/LBL PREDICT FOR POOR SURVIVAL OF ADULT PATIENTS TREATED ON ALL PROTOCOLS
B. Ostrowska, G. Rymkiewicz, J. Romejko-Jarosinska, K. Domanskaczyz, E. Paszkiewicz-Kozik, L. Poplawska, K. Blachnio, E. Kraszewska, J. Walewski (MSCMCC, Warsaw, Poland)
 
0720 RITUXIMAB-CHOP EVERY 14 DAYS IN NAIVE PATIENTS WITH DIFFUSE B-LARGE CELL LYMPHOMA
L. Palomera, A. Rubio-Martínez, J.A. Angós, J.M. Domingo, J. Arguińano, F. Puente, M. Perella, P. Pilar, V. Recaséns, I. Sancho, P. Giraldo (Lozano Blesa University Hospital, Zaragoza, Spain)
 
0721 INFLUENCE OF SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR UPON TUMOR PROGRESSION IN PRIMARY SMALL INTESTINE LYMPHOMA
O. Karnabeda, N. Gaydukova (Kiev Medical Postgraduate Academy, Kiev, Ukraine)
 
0722 D-PACE REGIMEN: AN EFFECTIVE CHEMOTHERAPY REGIMEN TO CYTOREDUCE REFRACTORY AND EXTENSIVELY PRETREATED LYMPHOMAS BEFORE ALLOGENEIC STEM CELL TRASPLANTATION
N. Niccolň, F. Zallio, R. Milani, V. Montefusco, A. Dodero, A. Guidetti, A. Gianni, P. Corradini (Istituto Nazionale per lo Studio e la Cu, Milan, Italy)
 
0723 PROGNOSIS VALUE OF POSITRON EMISSION TOMOGRAPHY USING FLUORINE 18-FLUORODEOXYGLUCOSE IN THE SETTING OF ASCT IN PATIENTS WITH HIGH GRADE LYMPHOMA
V.R. Roland, C.B.M. Bodet-Milin, T.G. Gastinne, S.V. Vigouroux, P.M. Moreau, N.M. Milpied, F.K.B. Kraeber-Bodere, J.L.H. Harousseau, S.L.G. Le Gouill (Hotel Dieu, Nantes, France)
 
0724 LONG TERM SURVIVAL DATA OF PEDIATRIC NHL PATIENTS
V. Papadakis, A. Parcharidou, A. Paisiou, N. Tourkantoni, S. Papargyri, J.P. Panagiotou, A. Kyrantzopoulou, K. Stefanaki, S. Haidas, S. Polychronopoulou (Aghia Sophia Children's Hospital, Athens, Greece)
 
0725 PREVALENCE OF HEPATITIS B IN PATIENTS WITH HODGKIN AND NON-HODGKIN’S LYMPHOMAS
P. Konstantinidou, E. Verrou, E. Georgiou, C. Chatziaggelidou, C. Zervas, N. Constantinou (Theagenion Cancer Hospital, Thessaloniki, Greece)
 
0726 SAFETY AND EFFICACY OF RITUXIMAB COMBINED WITH CHEMOTHERAPY FOR LYMPHOMA DURING PREGNANCY
J. Rey, N. Bouayed, V. Roger, J.A. Gastaut, R. Bouabdallah, D. Coso (Institut Paoli-Calmettes, Marseille, France)
 
0727 FALSE POSITIVE PET FINDINGS IN NHL PATIENTS AFTER CHEMOTHERAPY RELATED TO MACROPHAGE-RICH LESIONS
M. Gomes, C. Pinto, P. Figueiredo, A.M. Leite (IPO Coimbra, Coimbra, Portugal)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES III

 
0728 DIVERSE NICHES WITHIN MULTIPLE MYELOMA BONE MARROW SAMPLES AFFECT PLASMA CELL ENUMERATION AND FCM PROFILE
N.L. Nadav, B.Z. Katz, S. Baron, L. Yossipov, A. Polliack, V. Deutsch, B. Geiger, E. Naparstek (Weizmann Institute of Science, Rehovot, Israel)
 
0729 COMBINATION OF BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) IN ADVANCED MYELOMA: A PHASE II CLINICAL TRIAL
A. Palumbo, M.T. Ambrosini, G. Benevolo, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Pregno, F. Gay, I. Avonto, C. Rus, P. Falco, S. Bringhen, M. Boccadoro (Divisione di Ematologia Univ. Torino, Torino, Italy)
 
0730 SERUM CONCENTRATIONS OF DICKKOPF-1 PROTEIN ARE INCREASED IN PATIENTS WITH MULTIPLE MYELOMA AND REDUCED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
M. Politou, D.J. Heath, A. Rahemtulla, R. Szydlo, A. Anagnostopoulos, M.A. Dimopoulos, P.I. Croucher, E. Terpos (Faculty of Medicine Imperial College, London, United Kingdom)
 
0731 DEVELOPMENT OF A NOD-SCID -HU ANIMAL MODEL TO INVESTIGATE WALDENSTRÖM'S MACROGLOBULINEMIA*
S. Tsingotjidou, S.E. Siotou, E. Emmanouilides, S.D. Sotiropoulos, P.T. Poutahidis, X.A. Xagorari, G. P. Givissis, F.A. Fassas, A.A. Anagnostopoulos (Aristotle University of Thessaloniki, Thessaloniki, Greece)
 
0732 COMBINATION OF BORTEZOMIB AND DEXAMETHASONE FOR PATIENTS WITH AL AMYLOIDOSIS
E. Kastritis, A. Anagnostopoulos, G. Bozas, S. Toumanidis, S. Mellou, J. Nanas, M.A. Dimopoulos (University of Athens, Athens, Greece)
 
0733 LENALIDAMIDE (REVLIMID), IN COMBINATION WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CRD) IS AN EFFECTIVE REGIMEN FOR HEAVILY PRE-TREATED MYELOMA PATIENTS
FE Davies, G.J. Morgan, S.A. Schey, P. Wu, M. Srikanth, K.J. Phekoo, M. Jenner, A. Field Smith, S. Dines, A. Qureshi, G. Ravindranathan, R. Saso, F.E. Davies (Royal Marsden Hospital, London, United Kingdom)
 
0734 ACQUIRED ACTIVATED PROTEIN C RESISTANCE , MULTIPLE MYELOMA AND THROMBOSIS DURING THE INDUCTION PHASE OF TREATMENT
V. Jimenez, V. Domínguez (Incmnsz, Mexico City, Mexico)
 
0735 INTERNATIONAL STAGING SYSTEM IN MULTIPLE MYELOMA: IS ALBUMIN TRULY NECESSARY IN THE MODEL?
D. Mihou, I. Katodritou, D. Markala, K. Zervas ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0736 MOLECULAR CHARACTERIZATION OF A PANEL OF MULTIPLE MYELOMA CELL LINES: A MODEL FOR AN INTEGRATIVE GENOMICS APPROACH
L. Lombardi, M. Mattioli, G. Poretti, S. Fabris, I. Kwee, S. Bicciato, L. Agnelli, D. Verdelli, A. Rinaldi, G. Lambertenghi-Deliliers, F. Bertoni, A. Neri (Fondazione IRCCS Ospedale Policlinico, Milano, Italy)
 
0737 MONOCLONAL GAMMOPATHY: NATURAL HISTORY STUDIED WITH A RETROSPECTIVE APPROACH
H. Steingrimsdóttir, V. Haraldsdottir, V. Gu?nason, I. Olafsson, H.M. Ogmundsdottir (Landspitali University Hospital, Reykjavik, Iceland)
 
0738 PHASE I STUDY OF BORTEZOMIB AND 153SM-LEXIDRONAM COMBINATION FOR REFRACTORY AND RELAPSED MULTIPLE MYELOMA
R. Swift, D. Ferretti, R. Mapes, W. Goeckeler, J. Berenson, H.S. Yeh (Institute for Myeloma & Bone Cancer Res, West Hollywood, USA)
 
0739 ANTI-THYMOCYTE GLOBULIN (ATG) INDUCES APOPTOSIS IN MYELOMA CELLS: A BASIS FOR MYELOMA SERO-THERAPY?
F. Ayuk, L. Fang, S. Mina, B. Fehse, N. Atassi, A.R. Zander, N. Kroger (University Medical Center Hamburg, Hamburg, Germany)
 
0740 IMMUNOGLOBULIN-LIKE TRANSCRIPT 2 (ILT2) IS NOT DIFFERENTIALLY EXPRESSED IN MGUS AND MYELOMA, BUT APPEARS TO BE DOWNREGULATED AT AN EARLIER STAGE OF PLASMA CELL DISEASE
M. Schreder, W. Hübl, G. Koch, K. Strasser-Weippl, N. Zojer, H. Ludwig (Wilhelminenspital, Vienna, Austria)
 
0741 A NEW MODEL PREDICTING AT LEAST A VERY GOOD PARTIAL RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER 2 CYCLES OF BORTEZOMIB-BASED THERAPY
J.F. Friedman, A. Al-Zoubi, M. Kaminski, T. Kendall, A. Jakubowiak (University of Michigan, Ann Arbor, USA)
 
0742 RARE OCCURRENCE OF T(4;14) AND P53 DELETION BUT HIGH INCIDENCE OF OTHER MYELOMA HIGH-RISK FEATURES (+1Q, +9Q, AND 13Q-) IN MGUS - ANALYSIS USING FISH AND DNA PROBES FOR THE DETECTION OF GENOMIC ABNORMALITIES INVOLVING 10 CHROMOSOMAL LOCI
C. Wendl, A. Greiner, H. Döhner, P. Liebisch (University Hospital of Ulm, Ulm, Germany)
 
0743 SCREENING OF JAK2 V617F MUTATION IN MULTIPLE MYELOMA
A. Fiorini, G. Farina, G. Reddiconto, M. Palladino, P. Chiusolo, V. De Stefano, L. Laurenti, S. De Matteis, F. Sorŕ, S. Giammarco, G. Zini, G. Leone, S. Sica (Universitŕ Cattolica del Sacro Cuore, Rome, Italy)
 
0744 OZONE THERAPY IN THE TREATMENT OF OSTEONECROSIS OF THE JAWS IN MULTIPLE MYELOMA PATIENTS
M.T. Petrucci, C. Gallucci, A. Agrillo, M. Tedaldi, G. Iannetti, R. Foŕ (University "La Sapienza" Roma, Roma, Italy)
 
0745 EFFECTS AND MOLECULAR MECHANISM OF LENALIDOMIDE ON FGFR SIGNALING IN ENDOTHELIAL CELLS AND FGFR3+ MULTIPLE MYELOMA CELL LINES
A. Gandhi, L. Zhang, L. Lu, B. Bartlett, J. Kang, P. Schafer, W. Sherman, D. Stirling (Celgene Corporation, Summit, USA)
 
0746 TUMOR ANGIOGENESIS AND SENSITIVITY TO THE IL-6 IN MULTIPLE MYELOMA: EXPRESSION OF THE MICROVESSEL DENSITY AND GP-130 INTERLEUKIN-6 TRANSDUCER WITHIN THE BONE MARROW COMPARTMENT
M Perunicic-Jovanovic, J. Bila, L.J. Jakovic, D. Tomin, V. Cemerikic- Martinovic, T. Terzic, M. Gotic, D. Boskovic (Institute of Hematology, CCS, Belgrade, Serbia and Montenegro)
 
0747 CORRELATION BETWEEN THE CYTOGENETIC FINDINGS AND THE PROGNOSTIC FACTORS IN THE GROUP OF PATIENTS FROM THE CMG 2002 CLINICAL STUDY
J. Smejkalova, P. Kuglik, H. Filkova, A. Oltova, Z. Adam, L. Pour, M. Krejci, M. Penka, R. Hajek (University Hospital, Brno, Czech Republic)
 
0748 LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY FOLLOWING SINGLE OR TANDEM AUTOTRANSPLANT IN ADVANCED MULTIPLE MYELOMA (MM) IMPROVES OVERALL RESPONSE WITH MILD TOXICITY
F.B. Benedetti (Centro Trapianto Midollo Osseo, Verona, Italy)
 
0749 PEGYLATED LIPOSOMAL DOXORUBICIN, MELPHALAN AND PREDNISONE THERAPY FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA
R.G.S. Garcia-Sanz, H.J.M. Hernández, A.S. Sureda, J.G.L. García- Larańa, F.P. Prósper, A.A. Alegre, A.B. Bárez, M.V.M. Mateos, J.S.M. San Miguel (Univercisty Hospital of Salamanca, Salamanca, Spain)
 
0750 INCREASED INHIBITORY, CD158A, RECEPTOR EXPRESSION ON CD16+NK CELLS AND IMPAIRED NK CELL CYTOTOXICITY IN ADVANCED MYELOMA PATIENTS
G.K. Konjevic, V. Jurisic, M. Colovic, K Mirjacic, A. Vuletic, T. Srdic, I. Minic, I. Spuzic (Inst of Oncolnd Radiol of Serbia, Belgrade, Yugoslavia)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES IV

 
0751 THE RISK OF THROMBOCYTOPENIA AND NEUROPATHY AFTER BORTEZOMIB THERAPY DEPENDS ON THE BASELINE PLATELET COUNTS AND PREVIOUS NEUROPATHY RESULTS OF CZECH MYELOMA GROUP (CMG)
I.S. Spicka (General Fac. Hosp. Prague, Prague, Czech Republic)
 
0752 BORTEZOMIB IN COMBINATION WITH LIPOSOMAL DOXORUBICIN AND THALIDOMIDE (VDT) IS AN ACTIVE SALVAGE REGIMEN IN PATIENTS(PTS) WITH RELAPSE (REL) OR REFACTORY (REF) MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE II STUDY
S. Padmanabhan, K. Miller, L. Musiel, Z. Bernstein, M. Czuczman, J. Yu, A. Chanan-Khan (Roswell Park Cancer Institute, Buffalo, Ny, USA)
 
0753 FLOW CYTOMETRIC IMMUNOPHENOTYPIC ANALYSIS OF 25 CASES OF PLASMA CELL LEUKEMIA
M. Kraj, R. Poglod, J. Kopec- Szlezak, K. Owczarska (Institute of Haematology and Blood Trans, Warsaw, Poland)
 
0754 INORGANIC POLYPHOSPHATE IS PRESENT AND INDUCES APOPTOSIS SPECIFICALLY IN HUMAN PLASMA CELLS
A. Ruiz, L. Hernandez-Ruiz, I. González-García, C. Castro, J.A. Brieva (Hospital U. Puerta del Mar, Cadiz, Spain)
 
0755 METHYLATION STATUS OF THE P57KIP2 GENE IN PATIENTS WITH PLASMA CELL DYSCRASIAS
E. Hatzimichael, A. Dasoula, A. Makis, M. Syrrou, K. Bourantas (Haematology Clinic, Ioannina, Greece)
 
0756 EVALUATION OF THE RELATION BETWEEN ANGIOGENIC CYTOKINES, SELECTED BIOLOGICAL PARAMETERS AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
V.S. Scudla, T.P. Pika, M.B. Budikova, M.O. Ordeltova, J.M. Minarik, M.Z. Zemanova, J.B. Bacovsky, K.S. Srovnalik (3rd Department of Internal Medicine, Olomouc, Czech Republic)
 
0757 COMPARISON OF SERUM LEVELS OF BIOLOGICAL PARAMETERS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA
V.S. Scudla, T.P. Pika, M.B. Budikova, J. M. Minarik, M.Z. Zemanova, J.B. Bacovsky, V.H. Heinzova (3rd Department of Internal Medicine, Olomouc, Czech Republic)
 
0758 RELATIONSHIP OF SERUM FREE LIGHT CHAIN LEVELS TO DEGREE OF MULTIPLE MYELOMA PROGESSION
T.P. Pika, V.S. Scudla, J.M. Minarik (3rd Department of Internal Medicine, Olomouc, Czech Republic)
 
0759 VEGF EXPRESSION AND MICROVESSEL DENSITY IN PATIENTS WITH MULTIPLE MYELOMA: CLINICAL AND PROGNOSTIC SIGNIFICANCE
O. Markovic, D. Marisavljevic, V. Cemerikic, M. Perunicic, M. Bakrac, A. Vidovic, I. Elezovic, M. Colovic (Medical Training Center "Bezanijska Kosa, Belgrade, Serbia and Montenegro)
 
0760 CLONOGENIC CAPACITY OF BONE MARROW CELLS IN PATIENTS WITH MULTIPLE MYELOMA. THE INFLUENCE OF ARSENIC TRIOXIDE AND BORTEZOMIB ON THE PROLIFERATION OF CFU-F AND CFU-GM
W.K. Knopinska-Posluszny, M.T. Taszner, A.H. Hellmann (Medical University School aboratory Diag, Gdansk, Poland)
 
0761 CHARACTERIZATION OF THE PLASMA CELLS OF MULTIPLE MYELOMA BY SERIAL ANALYSIS OF GENE EXPRESSION (SAGE)
M. Ortega, A. Cunha, D. Albuquerque, A. Duarte, C. De Souza, I. Lorand-Metze, F. Costa, C. Lima (State University of Campinas, Campinas, Brazil)
 
0762 THE PREVALENCE OF K-RAS AND N-RAS MUTATIONS IN BRAZILIAN PATIENTS WITH MULTIPLE MYELOMA
M. Ortega, R. Faria, A. Assis, D. Albuquerque, J. Oliveira, M. Noguti, J. Faria, F. Costa, C. Lima (State University of Campinas, Campinas, Brazil)
 
0763 RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS FOLLOWING ZOLEDRONIC ACID OR IBANDRONATE TREATMENT
L. Antrŕs, R. Weide, H. Köppler, M. Smith, M. Neary, J. Green, N. Wintfeld, M.S. Duh (Analysis Group, Inc, Boston, USA)
 
0764 LOW DOSE BORTEZOMIB, DEXAMETHASONE, THALIDOMIDE PLUS LIPOSOMAL DOXORUBICIN IN RELAPSED AND REFRACTORY MYELOMA
S.C. Ciolli (Careggi Hospital, Florence, Italy)
 
0765 ANALYSIS OF RESPONSE AND FOLLOW-UP IN RELAPSED REFRACTORY MYELOMA RECEIVING BORTEZOMIB
A. Rubio-Martínez, V. Recaséns, P. Delgado, J.C. García-Zueco, D. Rubio-Félix, P. Giraldo (Miguel Servet University Hospital, Zaragoza, Spain)
 
0766 TUMOR-HOST INTERACTIONS IN THE BONE MARROW OF MULTIPLE MYELOMA PATIENTS: ANALYSIS OF CLINICAL RELEVANCE AND PROGNOSTIC SIGNIFICANCE
J. Bila, M. Perunicic, I. Elezovic, M. Bakrac, N. Suvajdzic, M. Gotic, D. Tomin, A. Vidovic, V. Cemerikic, D. Boskovic (Institute of Hematology, Belgrade, Serbia and Montenegro)
 
0767 EPIGENETIC MODIFICATIONS OF THE DLK1/GTL2 IMPRINTED GENES IN MULTIPLE MYELOMA AND WALDENSTROM'S MACROGLODULINEMIA; PRELIMINARY RESULTS
L. Benetatos, A. Dasoula, E. Hatzimichael, I. Georgiou, A. Vassou, M. Syrrou, K. Bourantas (Medical School, University Hospital of I, Ioannina, Greece)
 
0768 A MULTICENTER RETROSPECTIVE ANALYSIS OF ADVERSE EVENTS IN KOREAN PATIENTS USING BORTEZOMIB FOR MULTIPLE MYELOMA
S. Bang, J. H. Lee, S. Park, C. Kim, S. K. Sohn, K. Kim, H. Yoon, C.S. Kim, Y.S. Kim, H.J. Shin, J.H. Won, G.W. Lee, H. Kim, H.Y. Kim, J.H. Kwon (Gil Medical Center, Incheon, South-Korea)
 
0769 FREQUENCY AND DISTRIBUTION OF TRISOMY 11 IN MULTIPLE MYELOMA PATIENTS : RELATION WITH OVEREXPRESSION OF CCND1 GENE AND T(11;14) TRANSLOCATION
T. Guglielmelli, E. Giugliano, S. Cappia, M. Papotti, G. Saglio (Univ. of Turin and St Luigi Hospital, Orbassano, Italy)
 
0770 RAPID DETECTION OF RESPONSE TO BORTEZOMIBE-BASED REGIMEN IN MULTIPLE MYELOMA USING FREE LIGHT CHAIN ASSAYS
R.H. Hajek, P. Pour, H. Novotna, Z. Cermakova, Z. Adam, M. Krejci, K. Havlikova (Faculty Hospital Brno, Brno, Czech Republic)
 
0771 BORTEZOMIB THERAPY IN MULTIPLE MYELOMA (MM). EXPERIENCE OUTSIDE THE CONTEXT OF A CLINICAL TRIAL
S. Sachanas, M.C. Kyrtsonis, Z. Galanis, V. Greca, T.P. Vassilakopoulos, K. Anargyrou, S. Chrysochoou, M. Dimou, G. Panagoulias, S.I. Kokoris, E.M. Dimitriadou, M.K. Angelopoulou, N. Viniou, P. Panayiotidis, G.A. Pangalis (University of Athens, Athens, Greece)
 
0772 BORTEZOMIB AS A SINGLE AGENT IN REFRACTORY/RELAPSED MULTIPLE MYELOMA RESULTS OF CZECH MYELOMA GROUP (CMG)
I.S. Spicka (General Fac. Hosp. Prague, Prague, Czech Republic)
 
0773 SYNERGISTIC GROWTH INHIBITION OF MALIGNANT PLASMA CELLS BY DEXAMETHASONE AND THE FARNESYLTRANSFERASE INHIBITOR L744.832
A. Ott, F. Bakker, K. Richter, T. Ahrens, R. Burger, A. Guenther, M. Gramatzki (2nd Medical Department, Kiel, Germany)
 

CLL AND RELATED DISORDERS - CLINICAL / EXPERIMENTAL II

 
0774 DEXAMETHASONE INDUCES APOPTOSIS "EX VIVO" IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH EITHER UNMUTATED IGVH GENES OR HIGH ZAP-70 EXPRESSION
A. Muntańola, M. Crespo, E. Gine, N. Villamor, E. Montserrat, F. Bosch (Hospital Clinic, Barcelona, Spain)
 
0775 CLL IN RADIATION EXPOSED AFTER CHERNOBYL: IMMUNOPHENOTYPIC AND PATHOLOGICAL FINDINGS
D. Bazyka, O. Polyschuk, N. Belyaeva, I. Ilyenko, I. Kryachok, V. Bebeshko (Research Center for Radiation Medicine, Kyiv, Ukraine)
 
0776 CYTOSOLIC HISTONE H1.2 RELEASING UNDER DIFFERENT APOPTOTIC STIMULI IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
E. Giné, M. Crespo, A. Muntańola, E. Montserrat, F. Bosch (Hospital Clínic, Barcelona, Spain)
 
0777 ZAP-70 EXPRESSION IN NEOPLASTIC CELLS AND T LYMPHOCYTES OF B-CLL PATIENTS: A REPRODUCIBLE METHOD FOR DETECTION USING FLOW CYTOMETRY
J. Caetano, M. Laiges, M. Gomes da Silva, T. Faria, M. Jorge, A. Parreira, P. Lúcio (Instituto Portuguęs de Oncologia, Lisboa, Portugal)
 
0778 A PHASE II STUDY OF THE COMBINATION OF ALEMTUZUMAB AND PENTOSTATIN IN PATIENTS WITH T-LYMPHOID MALIGNANCIES
F. Ravandi, H. Kantarjian, S. Faderl, S. Verstovsek, C. Koller, W. Wierda, A. Ferrajoli, F. Giles, M. Keating, S. O'Brien (University of Texas - MD Anderson, Houston, Texas, United States of America)
 
0779 WNT5B EXPRESSION: A NEW POTENTIAL PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA
C. Rabascio, L. Saronni, V. Raia, P. Mancuso, A. Calleri, C. Massaro, P. Antoniotti, J. Quarna, D. Laszlo, G. Martinelli, F. Bertolini (European Institute of Oncology, Milan, Italy)
 
0780 T CELL SUBSETS AND CMV INFECTION IN CLL: ASSOCIATIONS WITH IGVH MUTATIONAL STATUS, GENE USAGE AND CHROMOSOMAL ABERRATIONS
H.D. Alexander, C. Matthews, M.A. Catherwood, T.C.M. Morris (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0781 SERUM THYMIDINE KINASE LEVELS CAN IDENTIFY EARLY STAGE B-CLL PATIENTS WITH MUTATED IGVH GENES MOST LIKELY TO PROGRESS
H.D. Alexander, C. Matthews, M.A. Catherwood, T.C.M. Morris (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0782 DIAGNOSTIC POTENTIAL OF CD38 COMBINED WITH ZAP-70 EXPRESSION IN PREDICTING MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE REGION IN 450 CHRONIC LYMPHOCYTIC LEUKEMIA CASES
F. Morabito, G. Cutrona, M. Gentile, S. Matis, E. Vigna, S. Molinu, M. Colombo, M. Spriano, E. Rossi, G. Festini, C. Gentile, C. Stelitano, S. Molica, S. Zupo, V. Callea, M. Ferrarini, (Hematology Unit, Cosenza, Italy)
 
0783 VH3-48 AND VH3-53 GENE REARRANGEMENTS REPRESENT UNIQUE SUBGROUPS IN CLL AND ARE ASSOCIATED WITH BIASED LAMBDA LIGHT CHAIN RESTRICTION, HOMOGENOUS LCDR3 SEQUENCES AND POOR PROGNOSIS
H.D. Alexander, C. Matthews, M.A. Catherwood, T.C.M. Morris, (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0784 IDENTIFICATION OF NEW GENOMIC ALTERATIONS IN CLL USING A 32K BAC CGH ARRAY
R. Gunnarsson, J. Staaf, G. Jönsson, K. Karlsson, K. Willander, Ĺ. Borg, G. Juliusson (Lund University, Lund, Sweden)
 
0785 EVALUATION OF TRANSFERRIN RECEPTOR 1 AND 2 EXPRESSION AT THE RNA AND PROTEIN LEVEL IN NORMAL B CELLS VS. CHRONIC LYMPHOCYTIC LEUKEMIA
I. Chiotoglou, M. Samara, T. Smilevska, K. Stamatopoulos, C. Belessi, S. Lykousi, N. Stavroyianni, G. Paterakis, N. Stathakis, N. Laoutaris, A. Fassas, A. Anagnostopoulos, P. Kollia (University of Thessaly Medical School, Larissa, Greece)
 
0786 NEW PATHWAYS INVOLVED IN APOPTOSIS INHIBITON IN CHRONIC LYMPHOCYTIC LEUKEMIA
R. Proto-Siqueira (Faculty of Medicine of Ribeirao Preto, Ribeirao Preto, Brazil)
 
0787 T-CELL TYPE LYMPHOPROLIFERATIVE DISEASE OF GRANULAR LYMPHOCYTES (LDGL) IS EQUIPPED WITH A PHENOTYPIC PATTERN TYPICAL OF EFFECTOR CYTOTOXIC CELLS
R. Zambello, I. Baesso, L. Pavan, E. Boscaro, M. Miorin, M. Facco, N. Maschio, L. Trentin, C. Agostini, G. Semenzato (Padua University School of Medicine, Padova, Italy)
 
0788 LOW-DOSE ALEMTUZUMAB MONOTHERAPY IN ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
A. Cortelezzi, M.C. Pasquini, G. Reda, F. Ripamonti, B. Sarina, W. Barcellini, G. Lambertenghi Deliliers (Fondazione Policlinico Universitŕ Milano, Milan, Italy)
 
0789 ALLOGENEIC STEM CELL TRANSPLANTATION AND CHRONIC LYMPHOCYTIC LEUKEMIA: DISTINCT IMMUNOGLOBULIN VARIABLE HEAVY CHAIN GENES AS A POSSIBLE PROGNOSTIC INDICATOR
I. Panovska-Stavridis, L. Cevreska, M. Ivanovski, L. Hadzi-Pecova, A. Stojanovik, B. Georgievski (Medical Faculty-Skopje, Skopje, Macedonia)
 
0790 REVERSAL BONE MARROW ANGIOGENESIS AFTER COSOLIDATION THERAPY WITH ALEMTUZUMAB IN ADVANCED CLL
S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, E. Morra (A.O. Pugliese-Ciaccio, Catanzaro, Italy)
 
0791 FLUDARABINE AND CYCLOPHOSPHAMID (FC) VERSUS CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (CVP) AS FIRST LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
T.H. Abdelhamid, N. Al-lahloby, A. Kamel, N. Elsharkawy, A. Zaher, N. Francis (National Cancer Institute, Cairo, Egypt)
 
0792 ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE IN UNTREATED PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA. A PILOT STUDY
L. Laurenti, A. De Padua, M. Tarnani, P. Piccioni, A.M. Wahlstrom, M. Garzia, N. Piccirillo, G. Zini, A. Fiorini, G. Farina, C. Rumi, S. Marietti, S. Sica, G. Leone (Istituto di ematologia UCSC-Roma, Roma, Italy)
 
0793 CYTOGENETIC CHARACTERIZATION OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA / B-CELL SMALL LYMPHOCYTIC LYMPHOMA (B-CLL/B-SLL)
A.I. Zakharova, T.N. Obukhova, Y.Y. Lorie, E.V. Domracheva (National Center for Hematology, Moscow, Russian Federation)
 
0794 IGVH MUTATIONAL STATUS, VH GENE USAGE, GENDER AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
H.D. Alexander, C. Matthews, M.A. Catherwood, T.C.M. Morris, (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0795 VH GENE USAGE AND SOME FEATURES OF DISEASE COURSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
N. Bilous, I. Abramenko, I. Kryachok, Z. Martyna, A. Chumak, I. Phylonenko, T. Serbynenko (Research Centre for Radiation Medicine, Kiev, Ukraine)
 
0796 EFFICACY OF RITUXIMAB IN HAIRY CELL LEUKEMIA
M.K. Angelopoulou, S.I. Kokoris, P. Tsaftaridis, E. Plata, F.N. Kontopidou, E.M. Dimitriadou, T.P. Vassilakopoulos, M.P. Siakantaris, Z. Galani, C. Kalpadakis, S. Sachanas, M.C. Kyrtsonis, P. Korkolopoulou, P. Panayiotidis, G.A. Pangalis, M.N. Dimopoulou, (National and Kapodistrian University of, Athens, Greece)
 

QUALITY OF LIFE AND COST EFFECTIVENESS

 
0797 SUCCESSFUL AND COST-EFFECTIVE PROPHYLAXIS AND TREATMENT OF TUMOR LYSIS SYNDROME (TLS) WITH LOW DOSES OF RASBURICASE
M. Hummel, D. Buchheidt, A. Adam, M. Kripp, L. Sadikaj, S. Reiter, R. Hehlmann (III. Medizinische Klinik Mannheim, Mannheim, Germany)
 
0798 COST-EFFECTIVENESS OF LENALIDOMIDE IN THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS IN THE UNITED KINGDOM
C. Schaefer, F. Goss, A. Szende, G. Morgan, M Wang (Covance Market Access Services, Gaithersburg, USA)
 
0799 IMPROVEMENT IN HEMOGLOBIN LEVELS AND QUALITY OF LIFE IN ANEMIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING EPOETIN ALFA DURING CHEMOTHERAPY: RESULTS FROM THE EPOLYM TRIAL
C. Gisselbrecht, N. Marschner, G. Avvisati, - For EPOLYM Investigators (Hôpital Saint-Louis, Paris, France)
 
0800 COST AND COST-EFFECTIVENESS OF FLUCAM VERSUS FCR IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S.T Thompson, F.N. van Nooten, M.A. van Agthoven, P.H. Huijgens (Schering AG, Berlin, Germany)
 
0801 DYSMETABOLIC SYNDROME IN YOUNG SURVIVORS OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
M. Moschovi, G. Trimis, G. Chrousos, I. Papassotiriou, F. Tzortzatou-Stathopoulou (Athens University, Athens, Greece)
 
0802 PAIN IN HAEMATOLOGY: AN OUTCOME RESEARCH PROJECT |TO EVALUATE THE EPIDEMIOLOGY, PATHOPHYSIOLOGY AND EFFECTS OF PAIN TREATMENT IN IN-HOSPITAL PATIENTS
P.N. Niscola, C.L. Cupelli, R.C. Romani, G.M. Giovannini, P.D. Piccioni, O.L. Ottaviani, M.M. Mirabile, T.A. Tendas, N.B. Neri, T. Dentamaro, M.L. Maurillo, R. Marra, E. Angelucci, P. De Fabritiis (Sant'Eugenio Hospital, Roma, Italy)
 
0803 COST-EFFECTIVENESS OF 90Y-IBRITUMOMAB TIUXETAN (90Y-ZEVALIN) VERSUS RITUXIMAB MONOTHERAPY IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA
S.T. Thompson, F.N. van Nooten, M.A. van Agthoven (Schering AG, Berlin, Germany)
 
0804 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIC PATIENTS: A BRAZILIAN PERSPECTIVE
A. Calabro, T.E. Delea, O. Sofrygin, T.D. Coates, P. Phatak, A. Araújo (Novartis Biocięncias S.A., Săo Paulo, Brazil)
 
0805 COST EFFECTIVENESS OF ADDING IMATINIB TO CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOMEPOSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: AN EXPLORATORY ANALYSIS
W. Feng, T. Tran, M. Stephens, F. Botteman (Novartis Pharmaceuticals Corporation, Florhem Park, USA)
 
0806 MASS NEONATAL CORD BLOOD SCREENING: COST-EFFECTIVE IDENTIFICATION OF HAEMOGLOBINOPATHIES
V. Pathare, S. Al Kindi, S. AlZadjali, Q. Al Abri, H. Al Haddabi, S. Muralitharan, M. Mathews, D. Dennison, R. Krishnamoorthy (Sultan Qaboos University, Muscat, Oman)
 
0807 FOLLOWING THE CASE OF ESSENTIAL TROMBOCYTOSIS CAUSED BY NOURISHING DEFICIENCY
C. Malem (Laboratory Claudio Malem & Associated, General Alvear, Argentina)
 
0808 VALUE OF TRANSFUSION-FREE LIVING IN MDS: RESULTS OF HEALTH UTILITY INTERVIEWS WITH PATIENTS
A. Szende, C. Schaefer, F. Goss, M. Wang, K. Heptinstall (Covance Market Access Services, Leeds, United Kingdom)
 
0809 HEALTH RELATED QUALITY OF LIFE IS COMPROMISED IN PATIENTS WITH IRON OVERLOAD RECEIVING INFUSION TREATMENT: US AND UK SF-36 AND CHQ SCORES COMPARED TO MATCHED POPULATION NORMS
D. Rofail, M. Viala, E. Trudeau, J.F. Baladi, K.A. Payne (Mapi Values Ltd, Bollington, United Kingdom)
 
0810 ESTIMATED TOTAL ANNUAL COSTS OF INFUSED IRON CHELATION THERAPY IN THE UNITED KINGDOM
M.P. Desrosiers, K. Payne, I. Proskorovsky, K. Ishak, J.F. Baladi (Caro Research Institute, Montreal, Canada)
 
0811 SAFETY, EFFICACY AND COST-EFFECTIVENESS OF REGULAR PROPHYLAXIS WITH REFACTO IN ADULTS WITH SEVERE HEMOPHILIA A: A PROSPECTIVE STUDY
A. Gringeri, M. Monzini, S. Ravera, C. Santoro, R. Musso, L. Mantovani (University of Milan, Milano, Italy)
 
0812 COST UTILITY ANALYSIS OF DEFERASIROX VERSUS DEFEROXAMINE FOR PATIENTS REQUIRING IRON CHELATION THERAPY IN THE UNITED KINGDOM
J. Karnon, R.L. Akehurst, N.L. Papo (University of Sheffield, Sheffield, United Kingdom)
 
0813 COST-EFFECTIVENESS OF ALEMTUZUMAB IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE FAILED ALKYLATING AGENTS AND FLUDARABINE
S.T. Thompson, F.N. van Nooten, M.A. van Agthoven, P.H. Huijgens (Schering AG, Berlin, Germany)
 
0814 QUALITY MANAGEMENT SYSTEM FOR JACIE ACCREDITATION AT MINIMAL FINANCIAL COST
S. van Steenweghen, A. Gadisseur, A. Van de Velde, E. Steel, I. Vrelust, K. Van Brussel, Z. Berneman, W. Schroyens (Universitair Ziekenhuis Antwerpen, Edegem, Belgium)
 
0815 ESSENTIAL THROMBOCYTHAEMIA: ANAGRELIDE OR INTERFERON- A COST-UTILITY ANALYSIS
E.C.F. Wilson, R. Fordham (University of East Anglia, Norwich, United Kingdom)
 

ALLOGENEIC STEM CELL TRANSPLANTATION II

 
0816 IMMUNOLOGIC RECOVERY AND GRAFT VERSUS HOST DISEASE AFTER NONMYELOABLATIVE STEM CELL TRANSPLANTATIONS
J. Bennani, N. Meuleman, P. Lewalle, P. Martiat, A.I. Ahmad, M. Aoun, W. Ferremans, R. Leroy, M. Paesmans, D. Bron (Jules Bordet Institute, Brussels, Belgium)
 
0817 LOW-DOSE METHOTREXATE AS SALVAGE THERAPY FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER REDUCED-INTENSITY CONDITIONING (RIC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
M. Mohty, H. De Lavallade, C. Faucher, S. Furst, J. El Cheikh, D. Blaise, M. Mohty (Institut Paoli-Calmettes, Marseille, France)
 
0818 OBSERVATION-BASED EARLY WARNING SCORES TO DETECT IMPENDING CRITICAL ILLNESS PREDICT IN-HOSPITAL AND OVERALL SURVIVAL IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
M. von Lilienfeld-Toal, K. Midgley, S. Lieberbach, L. Barnard, A. Glasmacher, M. Gilleece, G. Cook (Uniklinik Bonn, Bonn, Germany)
 
0819 A DOSE FINDING STUDY OF IV BUSULFAN IN COMBINATION WITH CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN PRIOR ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HAEMATOLOGICAL DISEASES: OPTIMISATION OF BUSULFAN TREATMENT
H. Esperou, F. Méchinaud, G. Michel, C. Galambrun, B. Neven, K. Yacouben, P. Bordigoni, C. Paillard, H. Zouabi, C. Levrault, V. Cadic, L. Nguyen, G. Vassal (Hôpital Saint-Louis, Paris, France)
 
0820 DACLIZUMAB HAS POOR EFFICACY IN STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE WITH 12 ALLOGRAFT PATIENTS
H. Sia, C.H. Hui, H. Mangos, N. Horvath, H.K. Lee, I. Lewis, T. Hughes, B. To, P. Bardy (Royal Adelaide Hospital, Adelaide, Australia)
 
0821 ALLOGENEIC STEM CELL TRANSPLANTATIONS AFTER REDUCED INTENSITY CONDITIONING REGIMEN FLUDARABIN, BUSULFAN AND ATG
Y. Brychtova, M. Doubek, J. MuĎík, J. Mayer, J Vorlícek (University Hospital Brno, Brno, Czech Republic)
 
0822 LOW-DOSE METHOTREXATE AS SALVAGE THERAPY FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER REDUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
H. de Lavallade, M. Mohty, C. Faucher, S. Furst, J. El Cheikh, D. Blaise (Institut Paoli-Calmettes, Marseille, France)
 
0823 BETA THALASSAEMIA MAJOR: BONE MARROW VERSUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
M. Irfan, S. Adil, P. Ahmed, S. Ansari, T. Farzana, K. Hashmi, B. Khan, V. Panjwani, T. Shamsi (Bismillah Taqee Blood Disease Centre, Karachi, Pakistan)
 
0824 ALLOGENEIC STEM CELL TRANSPLANTATION 1985-2005. A SINGLE CENTER EXPERIENCE
Y. Floisand, B. Fossum Lřland, J. Rřislien, G.E. Tjřnnfjord, T. Gedde-Dahl d.y, S.A. Evensen, D. Heldal, T. Egeland, B.G. Solheim, D. Albrechtsen, L. Brinch (Rikshospitalet National Hospital, Oslo, Norway)
 
0825 EXTRACORPOREAL RADIOPHERESIS FOR ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE
M. Velasquez-Lopera, F. Cuellar-Ambrosi, L.A. Correa, J.C. Wolff, C. Fonseca, M. Rojas, L.F. Garcia (Universidad de Antioquia, Medellin, Colombia)
 
0826 IMMUNOHISTOCHEMICAL EVALUATION OF INFILTRATING CELLS (CD4+, CD8+, AND CD56+) AND LANGERHANS CELLS IN SKIN OF GRAFT VERSUS HOST DISEASE PATIENTS
M. Velasquez-Lopera, A. Vargas, G. Arellano, L.A. Correa, J.C. Wolff, G. Sanclemente, J.C. Villamizar, A. Jaramillo, L.F. Garcia, F. Cuellar-Ambrosi (Universidad de Antioquia, Medellin, Colombia)
 
0827 DYNAMICS OF LINEAGE-SPECIFIC CHIMERISM IN PATIENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION
O. Horky, J. Mayer, M. Borsky, J. Pospisilova, M. Krejci, D. Dvorakova (Faculty Hospital Brno, Brno, Czech Republic)
 
0828 ALLOGENEIC BONE MARROW TRANSPLANTATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
S. Cantero, J. De la Rubia, M. Blanes, G. Sanz, J. Martinez, J.I. Lorenzo, A. Sempere, N. Puig, L. Algarra, G. Martin, C. Jimenez, M.A. Sanz (Hospital La Fe, Valencia, Spain)
 
0829 "INDACTION INSTEAD OF INDUCTION": NON-INTENSIVE AML/MDS TREATMENT WITH LOW-DOSE DECITABINE PRIOR TO REDUCED-INTENSITY CONDITIONING (RIC) AND ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION OF OLDER PATIENTS
M Lübbert, H. Bertz, B. Rüter, R. Mertelsmann, J. Finke (University of Freiburg, Freiburg, Germany)
 
0830 ALLOGENEIC STEM CELL TRANSPLANTION IN MULTIPLE MYELOMA
A.M. Carella, M.M. Greco, M. Nobile, P. Musto, L. Savino, M. Centra, G. Di Giorgio, M. Troiano, E. Piazzolla, S. Parisi, N. Cascavilla (IRCCS "CSS" Hospital, San Giovanni Rotondo, Italy)
 
0831 TACROLIMUS AND METHOTREXATE FOR THE PROPHYLAXIS OF GRAFT-VERSUS- HOST DISEASE AFTER UNRELATED DONOR CORD BLOOD TRANSPLANTATION FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES
T.M. Mori, T. Nakazato, A. Aisa, R. Yamazaki, A. Mihara, Y. Ikeda, S. Okamoto (Keio University School of Medicine, Tokyo, Japan)
 
0832 INCREASING MIXED CHIMERISM DETECTED WITH SHORT TANDEM REPEATS (STR) DEFINES A GROUP OF PATIENTS WITH POOR OUTCOME AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC PERIPHERAL BLOOD STEM-CELL TRANSPLANTATION (RIC ALLOPBSCT) WHICH CAN BE IMPROVED BY IMMUNOTHERAPY
M. Alcoceba, A. Balanzategui, P. Martín-Jiménez, M.E. Sarasquete, M.C. Chillón, C. Santamaría, L. Marín, R. García-Sanz, D. Caballero, J.F. San Miguel, M. González (Hospital Universitario de Salamanca, Salamanca, Spain)
 
0833 SERIAL ANALYSIS OF WHOLE BLOOD CELL AND CD3+ T-LYMPHOCYTE CHIMERISM FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION WITH ALEMTUZUMAB CONTAINING REDUCED-INTENSITY-CONDITIONING (RIC)
S.J. Tauro, R. Lovell, G. Begum, D.J. McMullan, M.J. Griffiths, F.J. Clark, M.A. Cook, P. Mahendra, D.W. Milligan, C.F. Craddock (University Hospital Birmingham, Birmingham, United Kingdom)
 
0834 CHIMERISM STATUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
L. Savino, A.M. Carella, M.M. Greco, M. Nobile, N. Cascavilla (IRCCS Casa Sollievo Della Soffererenza, San Giovanni Rotondo, Italy)
 
0835 HEMATOPOIETIC RECOVERY AFTER LOW INTENSITY CONDITIONING TRANSPLANTS AND STANDARD ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARATIVE ANALYSIS
G. Kostova, D. Heim, J. Passweg, A. Buser, A. Tichelli, A. Gratwohl (Clinic for Hematology, Skopje, Macedonia)
 
0836 ANTITHYMOCYTE GLOBULIN THERAPY FOR STEROIDRESISTANT ACUTE GRAFT VERSUS HOST DISEASE
M. Ballesteros, C. Ferrá, N. Hernández de León, M. Batlle, D. Serrano, R. Carrión, B. Xicoy, P. Balsalobre, J.M. Ribera, J.L. Diez-Martín (Gregorio Marańón Hospital, Madrid, Spain)
 
0837 CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING REGIMEN
E. Elli, M. Parma, F. Rossini, E. Terruzzi, P. Pioltelli, E. Pogliani (Ospedale San Gerardo, Monza, Italy)
 
0838 EARLY AND LATE COMPLICATIONS OF FAMILIAL ALLOGENEIC BONE MARROW TRANSPLANTATION. A SINGLE PAEDIATRIC CENTER EXPERIENCE
R. Parasole, G. Menna, G. De Simone, A. Mangione, V. Poggi, M. Ripaldi (Pausilipon Hospital, Naples, Italy)
 

CYTOKINES AND GROWTH FACTORS

 
0839 ERYTHROPOEITIN (EPO) AS AN IMMUNOMODULATORY AGENT: EPO-ASSOCIATED B CELL PROLIFERATION
O.K. Katz, L.L. Lifshitz, B.C.N. Ben-Califa, P.S. S. Prutchi-Sagiv, G.M. Gassmann, M.M. Mitelman, N.D. Neumann (Tel-Aviv University, Tel-aviv, Israel)
 
0840 IL-10 GENE POLYMORPHISM INFLUENCE THE CLINICAL COURSE OF NON-HODGKIN'S LYMPHOMA
J. Mazur, K. Bogunia-Kubik, T. Wróbel, K. Kuliczkowski, A. Lange (Wroclaw Medical University, Wroclaw, Poland)
 
0841 EFFECT OF PTH (1-34) ON HOMING OF HEMATOPOIETIC STEM CELLS
D. Svinareva, I.N. Nifontova, J.L. Chertkov, N.J. Drize (National Hematology Research Centre, Moscow, Russian Federation)
 
0842 SPONTANEOUS TRANSFORMATION OF LYMPH NODE AND BONE MARROW STROMAL CELLS FROM CANCER PATIENTS
L. Kideryova, R. Pytlik, T. Soukup, J. Karbanova, L. Kucerova, S. Micuda, H. Ruckerova, P. Cervinkova, M. Trneny, J. Mokry, P. Klener (1st Medical Faculty, Praha 2, Czech Republic)
 
0843 DOWN REGULATION OF ACTIVIN A BY LYMPHOMA IN THE BONE MARROW: A POSSIBLE MECHANISM OF BONE MARROW INVOLVEMENT
M.Z. Haran, R. Parmawasan, E. Feldberg, M. Fogel, A. Berrebi, M. Shtalrid, L. Shvidel, A. Duek, A. Nagler, M. Leiba, D. Zippori (Kaplan Medical Center, Rehovot, Israel)
 
0844 EVALUATION OF THE EXPRESSION OF ANGIOGENIC CYTOKINES AND THEIR RECEPTORS IN AUTOIMMUNE MYELOFIBROSIS
R. Rizzi, G. Guaragna, E. Rinaldi, A. Napoli, D. Pastore, G. Specchia, R. Ricco, V. Liso (Bari University Medical School, Bari, Italy)
 
0845 PROINFLAMMATORY CYTOKINES IN THE PATHOGENESIS OF DENGUE FEVER (DF) AND HAEMORRHAGIC DENGUE FEVER (HDF) IN VENEZUELA
N. Soyano, A. Müller, A.E. Soyano, C. Cruz, E. Olivo (Venezuelan Inst. for Scientific Research, Caracas, Venezuela)
 
0846 EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ON DECREASED IL-12P40 PRODUCTION BY CHEMOTHERAPY
T.T. Toubai, J.T. Tanaka, S.O. Ota, T.F. Fukuhara, S.H. Hashino, T.K. Kondo, M.M. Morioka, T.K. Kawamura, N.M. Masauzi, Y.K. Kakinoki, H.K. Kobayashi, Y.K. Kunieda, M.K. Kasai, H.I. Iwasaki, M.A. Asaka, M.I. Imamura (Hokkaido University, School of Medicine, Sapporo, Japan)
 
0847 ANGIOGENIC MOLECULES IN HODGKIN'S DISEASE: RESULTS FROM SEQUENTIAL SERUM ANALYSIS
F.H. Passam, A. Sfiridaki, G. Tzirakis, J. Moschandrea, P. Roussou, N. Siafakas, M.G. Alexandrakis (Sotiria Hospital, Medical School Athens, Athens, Greece)
 
0848 LEVELS OF CYTOKINES AND OTHER INFLAMMATORY MARKERS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
D. Hawrylecka, B. Kusnierz-Cabala, P. Mensah-Glanowska, B. Piatkowska-Jakubas, J. Naskalski, A.B. Skotnicki (Jagiellonian University, Krakow, Poland)
 
0849 TNF-ALPHA INDUCES APOPTOSIS IN CELLS UNDER ERYTHROID DIFFERENTIATION
D. Vittori, G. Pérez, A. Nesse (Universidad de Buenos Aires, Ciudad De Buenos Aires, Argentina)
 
0850 DEVELOPMENT OF MALIGNANCIES IN MICE TREATED WITH G-CSF FOR A LONG TIME
I.N. Nifontova, D.A. Svinareva, J.L. Chertkov, N.J. Drize, V.G. Savchenko (National Hematology Research Centre, Moscow, Russian Federation)
 
0851 PALIFERMIN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) - PRELIMINARY RESULTS
B. Nasilowska-Adamska, P. Rzepecki, J. Manko, M. Markiewicz, A. Czyz, I. Fedorowicz, A. Tomaszewska, B. Piatkowska-Jakubas, A. Wrzesien-Kus, D. Duda, K. Halaburda, A. Szczepinski, K. Warzocha, B. Marianska (Institute of Hematology and Blood Transf., Warsaw, Poland)
 
0852 EFFECTIVE MOBILIZATION BY PEG-FILGRASTIM PLUS ARA-C CONTAINING REGIMEN IN PRETREATED LYMPHOMAS PATIENTS
V. Pavone, A. Rana, F. Gaudio, C. Del Casale, A. Guarini, R. De Francesco, A. Mele, G. Greco, V. Liso (Azienda Ospedalira ''card. Panico'', Tricase (le), Italy)
 
0853 LOW DOSE LENOGRASTIM (L) IS AS EFFECTIVE AS STANDARD DOSE IN SHORTENING NEUTROPHIL ENGRAFTMENT TIME FOLLOWING MYELOABLATIVE CHEMOTHERAPY (HDT) AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE (PBPCR)
D.F.L. Nolan, P.W. Johnson, S. Chilton, P. Lorigan, R. Else, P. Smith, J.W. Sweetenham (Southampton General Hospital, Southampton, United Kingdom)
 
0854 MODULATION OF PROTEIN TYROSINE PHOSPHATASE 1B BY ERYTHROPOIETIN IN UT-7 CELL LINE
M. Callero, G. Perez, D. Vittori, A. Nesse (Buenos Aires University, Buenos Aires, Argentina)
 
0855 PLASMA CYTOKINE PROFILE IN HEALTHY INFANTS IS NOT INFLUENCED BY VACCINATION
J.L.A.J. Rummens, M. Raes, H. Jongen, V. Peeters, P. Scholtens, B. Maes, K. Hensen (Virga Jesse Hospital, Hasselt, Belgium)
 
0856 PRO-INFLAMMATORY CYTOKINES AND ATHEROSCLEROSIS IN CHILDREN
N. Lefkou, E. Ioannidou, V. Garipidou, S. Vakalopoulou, V. Perifanis, K. Tziomalos, M. Athanasiou, I. Tsiouris, I. Klonizakis (Ippokrateion University Hospital, Thessaloniki, Greece)
 
0857 MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND INTERLEUKIN-8 LEVELS IN ACUTE INFLAMMATION INDUCED BY PROLONGED BRISK EXERCISE: CLINICAL IMPLICATIONS
I. Papassotiriou, M. Tsironi, K. Skenderi, G. Chrousos (Aghia Sophia Children's Hospital, Athens, Greece)
 
0858 EVALUATION OF THE EFFECTS OF THE CD33-TARGETED DRUG OZOGAMICIN ON GROWTH AND HISTAMINE RELEASE IN HUMAN MAST CELLS AND BASOPHILS
M.T. Krauth, A. Böhm, H. Agis, K. Sonneck, S. Florian, K. Sotlar, P. Valent (Medical University of Vienna, Vienna, Austria)
 
0859 ALTERATIONS IN GENE EXPRESSION IN MURINE LEUKEMIA CELLS DEVELOPED AFTER G-CSF TREATMENT
A. Bigildeev, L . Grishchuk, A. Bigildeev, N. Nifontova, A . Svinareva, J. Drize, G Savchenko (National Hematology Research Centre, Moskow, Russian Federation)
 
0860 A SINGLE FIXED DOSE INJECTION OF PEGFILGRASTIM TO MOBILISE AUTOLOGOUS STEM CELLS OF EXTENSIVELY PRE-TREATED LYMPHOMA AND MYELOMA PATIENTS; NOT ALWAYS SUCCESSFUL
P.F. Ypma, A.A. Muradin, P.W. Wijermans (HAGAziekenhuis, Leyenburg, The Hague, The Netherlands)
 
0861 CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS SOLUBLE RECEPTORS VEGFR-1 AND VEGFR-2 IN PATIENTS WITH LYMPHOID MALIGNANCY
D.W. Woszczyk, J. Gola, T. Gasinska, D. Ziaja, T. Urbanek, W. Kuczmik, U. Mazurek (Medical University of Silesia, Katowice, Poland)
 

STEM CELLS - BIOLOGY

 
0862 INCREASED MT1-MMP EXPRESSION IS INVOLVED IN G-CSFINDUCED MOBILIZATION OF HUMAN CD34+ HEMATOPOIETIC PROGENITOR CELLS
A. Avigdor, P. Goichberg, Y. Vagima, I. Petit, M. Tesio, I. Hardan, O. Perl, E. Rosenthal, I. Resnick, A. Nagler, T. Lapidot (The Chaim Sheba Medical Center, Tel-hashomer, Israel)
 
0863 ROLE OF SONIC HEDGEHOG FOR REGULATING THE PROLIFERATION, MIGRATION AND DIFFERENTIATION OF HEMANGIOBLAST IN THE MICROENVIRONMENT OF AGM REGION
W.L. Liu, W.L. Liu, J.R Fu, M. ZHENG, D. Ran, L. Luo, H.Y. Sun (TongJi Hospital, Tongji medical college, Wuhan, China)
 
0864 SONIC HEDGEHOG PROTEIN PROMOTE BONE MARROWDERIVED ENDOTHELIAL PROGENITOR CELL PROLIFERATION, MIGRATION AND VEGF PRODUCTION VIA PHOSPHATIDYLINOSITOL 3-KINASE/AKT SIGNALING PATHWAYS
J.R. Fu, J.R. Fu, W.L. Liu, M. Zheng, D. Ran, H.Y. Sun (TongJi Hospital, Tongji medical college, Wuhan, China)
 
0865 DIFFERENTIAL EXPRESSION OF P-GLYCOPROTEIN, BUT NOT OF MRP, LRP AND BCRP IN LEUKEMIC STEM CELLS AS COMPARED TO MORE DIFFERENTIATED CD34+ AML BLASTS
L.L. Figueiredo-Pontes, M.C. Pintao, L.C.O. Oliveira, L.F.F. Dalmazzo, R.H. Jacomo, A.B. Garcia, R.P. Falcao, E.M. Rego (Medical School of Ribeirao Preto, Ribeirao Preto, Brazil)
 
0866 IRON METABOLISM DURING HUMAN ERYTHROPOIESIS: EVIDENCE FOR A DIFFERENTIAL IMPACT OF TRANSCRIPTIONAL VS. POST-TRANSCRIPTIONAL CONTROL MECHANISMS
M. Samara, I. Chiotoglou, S. Lykousi, S. Samara, N. Stathakis, P. Liakos, P. Kollia (University of Thessaly Medical School, Larissa, Greece)
 
0867 THE SPLEEN AS AN EMBRYONIC HEMATOPOIETIC SITE: IDENTIFICATION OF FETAL SPLEEN PROGENITORS
E. Desanti, A. Cumano, R. Golub (Institut Pasteur, Paris, France)
 
0868 DIMINISHED PROTEASOMAL DEGRADATION RESULTS IN ACCUMULATION OF GFI1 PROTEIN LEVELS IN MONOCYTES
L.T. van der Meer, J.A.F. Marteijn, L. Emst, T. de Witte, J.H. Jansen, B.A. van der Reijden (University Medical Center Nijmegen, Nijmegen, The Netherlands)
 
0869 HIGHER CONSTITUTIVE NF-KB SIGNALING IS A DISTINCTIVE FEATURE OF UMBILICAL CORD BLOOD CD34+ PRECURSORS
R.A. Panepucci, R.T. Calado, V. Rocha, R. Proto-Siqueira, C.A. Scrideli, R.C.V. Carrara, A.R.D. Santos, A.B. Garcia, A.G. Araujo, W.A. Silva-Jr, M.A. Zago (CTCFundherp FMRP-USP, Ribeirao Preto, Brazil)
 
0870 CLOSE FUNCTIONAL SIMILARITIES BETWEEN HUMAN MESENCHYMAL STEM CELLS, PERICYTES AND FIBROBLASTS
D. Covas, R.A. Panepucci, A.M. Fontes, M. Orellana, K.L. Prata, L.C. Perez, A.G. Araujo, L. Neder, W.A. Silva Jr, M.A. Zago (University of S. Paulo, Ribeirao Preto, Brazil)
 
0871 IDENTIFICATION OF NOVEL REGULATORS OF HEMATOPOIETIC STEM CELL MOBILIZATION
C. Voermans, W. Lento, M. Uqoezwa, L. DiMascio, A. Chhotani, F. Rattis, T. Reya (Duke Univ.Med.Center, Usa / Amsterdam, The Netherlands)
 
0872 DEVELOPMENT OF AN IN VIVO MODEL FOR THE STUDY OF TAL-1 LEUKEMOGENESIS AND T-ALL LEUKEMIC STEM CELLS
P. Ballerini, F. Armstrong, M.C. Rouyez, P. Brunet de la Grange, J. Landman- Parker, P.H. Roméo, P. Ballerini, F. Pflumio (Hôpital Armand Trousseau, Paris, France)
 
0873 MESENCHYMAL STEM CELLS ARE EFFECTIVE AT PREVENTING BUT NOT TREATING GRAFT-VERSUS-HOST DISEASE
V. Tisato, K. Naresh, F. Dazzi (Imperial College, London, United Kingdom)
 
0874 THE SIDE POPULATION MAY PROVIDE THE LEUKEMIC STEM CELL COMPARTMENT COMPLEMENTARY TO THE CD34+CD38- STEM CELL COMPARTMENT. IMPLICATIONS FOR STEM CELL MRD DETECTION AND THERAPEUTIC TARGETING
B. Moshaver, M. van der Pol, G. Westra, N. Feller, A. Kelder, A. van Rhenen, G.J. Ossenkoppele, S. Zweegman, G.J. Schuurhuis (VU medical center, Amsterdam, The Netherlands)
 
0875 HUMAN UMBILICAL CORD BLOOD CELLS REGENERATE HEPATOCYTES IN A NON-MYELOABLATIVE SETTING
S. Wong, G. Cheng, K. Tsang, D.F. Lau, N. Chan, W.S. WS, M.H. Ng, C. Tong, J.C. Tang, C.H. Chui (Prince of Wales Hospital, Hong Kong, Hongkong (China))
 
0876 TOWARD STANDARDIZATION OF CELLULAR PRODUCTS FOR IMMUNOMODULATION AND REGENERATIVE MEDICINE. EXPANSION OF MESENCHYMAL STEM CELLS DERIVED FROM AMNIOTIC FLUID: PERSPECTIVES OF FUTURE CLINICAL APPLICATION
N. Sessarego, M. Podesta, A. Parodi, M. Mogni, A. Ibatici, S. Pozzi, F. Bertolotti, M. Corselli, F. Dagna-bricarelli, F. Frassoni (Ospedale San Martino, Genoa, Italy)
 
0877 INTRACORONARY AUTOLOGOUS BONE-MARROW STEM CELL TRANSFER AFTER MYOCARDIAL INFARCTION. PRELIMINARY RESULTS OF A RANDOMISED TRIAL
J. Perez-Oteyza, P. Ramos, M. Catalan Sanz, M. Perez-Abad, M.J. Blanchard, C. Heras, P. Cuevas, E. Asin (Hospital Ramon y Cajal, Madrid, Spain)
 
0878 LOCAL INJECTION OF BONE MARROW CELLS AUGMENTS THE NEOVASCULARIZATION IN A MOUSE ISHEMIC HIND LIMB BY INDUCING VEGF
J.A. Kim, C.H. Lee, B.S. Lee (College of medicine,Catholic University., Suwon, South-Korea)
 

VASCULAR BIOLOGY, GRANULOCYTES AND INFECTIOUS DISEASES

 
0879 ABNORMALITIES OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
E. Stavroulaki, M.C. Kastrinaki, I. Mavroudi, G. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)
 
0880 CONGENITAL NEUTROPENIA: A GROUP OF DISORDERS WITH GENETIC AND PHENOTYPIC HETEROGENEITY
C. Zeidler, M. Germeshausen, B. Schwinzer, A. A. Bolyard, G. Pracht, B. Alter, M.A. Bonilla, B. Cham, J. Donadieu, C. Fier, M. Freedman, G. Kannourakis, S. Kinsey, L. Boxer, D.C. Dale, K. Welte (Medical School Hannover, Hannover, Germany)
 
0881 SUPERIOR EFFECTS OF HIGH DOSE ENZYME REPLACEMENT THERAPY IN TYPE 1 GAUCHER DISEASE ON BONE MARROW INVOLVEMENT AND CHITOTRIOSIDASE LEVELS; A TWO CENTER RETROSPECTIVE ANALYSIS
M. de Fost, C.E.M. Hollak, J.E.M. Groener, J.M.F.G. Aerts, M. Maas, L.W. Poll, M.G. Wiersma, D. Häussinger, S. Brett, N. Brill, S. vom Dahl (Academic Medical Center, Amsterdam, The Netherlands)
 
0882 LUNG RESECTION FOR INVASIVE PULMONARY ASPERGILLOSIS IN NEUTROPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES: LONG TERM RESULTS IN THIRTY CASES
T. Gastinne, C. Touzeau, V. Roland, S. Vigouroux, S. Le Gouill, B. Mahe, V. Dubruille, J. Delaunay, P. Chevalier, T. Guillaume, C. Sagan, F. Gay-Andrieu, P. Germaud, P. Despins, P. Moreau, J.L. Harousseau (Centre Hospitalier Universitaire, Nantes, France)
 
0883 THE ROLE OF DLL4 IN ENDOTHELIAL PROGENITOR CELL FUNCTION DURING TUMOUR ANGIOGENESIS
C. Real, R. Benedito, A. Duarte, S. Dias (Instituto Portuguęs de Oncologia- Lisboa, Lisboa, Portugal)
 
0884 PRESENT TRENDS IN THE MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
H. Cherif, M. Kalin, M. Björkholm (Karolinska Institution, Stockholm, Sweden)
 
0885 A SURVEY ON INVASIVE FUNGAL INFECTIONS IN SCT: TRENDS IN PROPHYLAXIS, TREATMENT, INCIDENCE AND CLINICAL OUTCOME AMONG 660 PATIENTS TRANSPLANTED DURING 2000-2004
J.F. Tomas, D. Serrano, J. de la Serna, M. Canales, J. Diaz-Mediavilla, J.L. Lopez-Lorenzo, S. Garcia, F. Hernandez, P. Garcia, M. Callejas, J.L. Diez-Martin (Hospital MD Anderson, Madrid, Spain)
 
0886 RANDOMIZED TRIAL OF PREVENTION OF CATHETER-RELATED BLOODSTREAM INFECTION IN PATIENTS WITH HEMATOLOGIC AND ONCOLOGIC DISEASE
A. Abdelkefi, W. Achour, S. Ladeb, T. Ben Othman, L. Torjman, A. Lakhal, A. Ben Hassen, A. Ben Abdeladhim (Centre National de Greffe de Moelle Osse, Tunis, Tunisia)
 
0887 POLYMORPHISMS OF MBL2, BUT NOT OF FCGRIIA AND MYELOPERODASE PROMOTOR GENES, INFLUENCE THE RISK OF SEPSIS IN MULTIPLE MYELOMA PATIENTS DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
I.M. Mřlle, N. Peterslund, R. Steffensen, S. Thiel (University of Aarhus, Aarhus, Denmark)
 
0888 DEVELOPMENT OF A FAST BROADBAND SCREENING SYSTEM FOR BACTERIAL BLOOD STREAM INFECTIONS USING WHOLE BLOOD AND CULTURE FLASKS
M. Handschur, H. Karlic, M. Pfeilstöcker, E. Pittermann, C. Disqué (Ludwig Boltzmann Institute, Vienna, Austria)
 
0889 31P MRS IN VITRO ASSAY OF PHOSPHOLIPIDS FROM PLASMA, PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), AND BONE MARROW MONONUCLEAR CELLS (BMMC) OF PATIENTS WITH ACUTE LEUKEMIA (AL) AT THE TIME OF DIAGNOSIS
M. Kuliszkiewicz-Janus, M.A. Tuz, M. Kielbinski, S. Baczynski, B. Jazwiec, I. Prajs (Wroclaw Medical University, Wroclaw, Poland)
 
0890 SAFETY OF A WEEKLY ADMINISTRATION OF 7.5 MG/KG OF LIPOSOMAL AMPHOTERICIN B (LAB) FOR ANTIFUNGAL PROPHYLAXIS IN PATIENTS RECEIVING HIGH DOSE CORTICOSTEROIDS (CS) FOR ACUTE GVHD AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION
M. Mohty, J. El Cheikh, C. Faucher, S. Furst, H. De Lavallade, D. Blaise (Institut Paoli-Calmettes, Marseille, France)
 
0891 IMMUNITY AGAINST POLIO, DIPHTHERIA AND TETANUS AFTER CONVENTIONAL CHEMOTHERAPY TREATMENT FOR AML AND HIGH-GRADE LYMPHOMA
S. Einarsdottir, P. Horal, P.O. Andersson, B. Kaijser, V. Karlsson, M. Brune (Sahlgrenska University hospital, Göteborg, Sweden)
 
0892 FLUOROCHINOLONE-RESISTANT ESCHERICHIA COLI IS THE MOST FREQUENT PATHOGEN ISOLATED FROM PATIENTS WITH HEMATOLOGIC MALIGNANCIES. RESULTS OF A PROSPECTIVE STUDY ON 364 CONSECUTIVE EPISODES OF FEVER AT A SINGLE INSTUTUTION
C. Cattaneo, G. Quaresmini, S. Casari, M.A. Capucci, M. Micheletti, E. Borlenghi, G. Rossi (U.O. Ematologia, Spedali Civili, Brescia, Italy)
 
0893 SIGNIFICANCE OF ENDOTHELIAL MICROPARTICLES, PLATELETS, AND LEUKOCYTE ACTIVATION IN PATIENTS WITH ACUTE CORONARY SYNDROME
M. Korzh, I. Kotchuev (Kharkov Medical Academy, Kharkov, Ukraine)
 
0894 CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPCS) IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS (AAV)
L. Kideryova, J. Zavada, R. Pytlik, P. Cervinkova, P. Klener, V. Tesar (1st Medical Faculty, Praha 2, Czech Republic)
 
0895 A RANDOMIZED COMPARATIVE STUDY OF RESPONSE TO EMPIRIC AMPHOTERICIN B DEOXYCHOLATE ON DAY 4 OR DAY 8 OF FEBRILE NEUTROPENIA
P. Malhotra, A. Makkar, N. Varma, A. Chakrabarti, S. Kumari, S. Jain, S. Varma (PGIMER, Chandigarh, India)
 
0896 THE NEURONOPATHIC SPECTRUM OF GAUCHER DISEASE: A SINGLECENTRE CLINICAL EXPERIENCE WITH 15 PAEDIATRIC PATIENTS
E. Mengel, C. Duck, R. König, Y. Amraoui, L. Arash, S. Pitz, M. Beck (Childrens Hospital Gutenberg-University, Mainz, Germany)
 
0897 CAUSES OF INCIDENTAL NEUTROPENIA IN ADULTHOOD
C. Lima, E. Paula, T. Takahashi, S. Saad, I. Lorand-Metze, F. Costa (State University of Campinas, Campinas, Brazil)
 
0898 LONG TERM FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS - A RETROSPECTIVE ANALYSIS
J.M.C.S. Costa Santos, M.J. Costa, J.A. Carmo, J.M. Fajardo, J.J. Gomes Oliveira (Santa Maria Hospital, Lisboa, Portugal)
 

THROMBOSIS II

 
0899 THE SAFETY AND EFFICACY OF CONTINUOUS DYNAMIC DOSE ANTICOAGULATION DURING CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
N. Polizzotto, S. Opat (The Alfred Hospital, Prahran, Australia)
 
0900 SURVIVAL IN MULTIPLE MYELOMA PATIENTS IS NOT AFFECTED BY DEVELOPMENT OR RECURRENCE OF THROMBOEMBOLISM
M.Z. Zangari, F.C. Cavallo, B.B. Barlogie, G.T. Tricot (Univ. of Arkansas for Medical Sciences, Little Rock, USA)
 
0901 LOW-DOSE WARFARIN DECREASES THE INCIDENCE OF THALIDOMIDE (T) ASSOCIATED VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
K. Miller, S. Padmanabhan, L. Musial, D. DePaolo, A. Chanan-Khan (Roswell Park Cancer Institute, Buffalo, USA)
 
0902 PRESCRIPTION OF LOW-MOLECULAR WEIGHT HEPARIN (LMWH) FOR PROPHYLAXIS AGAINST VENOUS THROMBO-EMBOLISM (VTE) IN MEDICAL PATIENTS
B. Myers, J. Wardle, J. Webb, J. Holmes (Queen's Medical Centre, University Hospi, Nottingham, United Kingdom)
 
0903 CENTRAL VENOUS CATHETER-RELATED THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SCREENING WITH DOPPLER-ULRASOUND
M. Kaptan, A. Ifran, C. Beyan, O. Nevruz (Gulhane Military Medical Academy, Ankara, Turkey)
 
0904 DOPPLER ULTRASOUND ASSESSMENT OF SUBCLAVIAN VENOUS BLOOD-FLOW AFTER THE IMPLANTATION OF A CENTRAL VEIN CATHETER IN CHILDREN WITH MALIGNANCY
T.O. Ociepa, E.M. Maloney, E.K. Kamienska, T.U. Urasinski, M.S. Sawicki, M.R. Rac, A.W. Walecka (Pomeranian Medical University, Szczecin, Poland)
 
0905 TIME COURSE OF INFLAMMATION AND PROTHROMBOTIC PARAMETERS IN ACUTE CORONARY SYNDROME
O. Gutierrez, A. Revilla, E. Fontecha, P.L. Sanchez, M. Dueńas, M.J. Peńarrubia, A. Cantalapiedra, I. Gomez, F. Fernandez-Aviles, L.J. Garcia Frade (Hospital U. Rio Hortega, Valladolid, Spain)
 
0906 ELECTIVE SURGERY IN ANTICOAGULATED ATRIAL FIBRILLATION PATIENTS WITHOUT BRIDGING THERAPY WITH LMWH
M.A. Cortés, M.L. González-Ponte (Hospital de Laredo, Laredo (cantabria), Spain)
 
0907 VALIDATION OF THE COMPUTERIZED DECISION SUPPORT SOFTWARE TAOCHECK TO MONITOR ORAL ANTICOAGULANT THERAPY
M.A. Cortés, E. Gómez, A. Hervás, R. Valero, P. Muńoz (Hospital de Laredo, Laredo (cantabria), Spain)
 
0908 RETROSPECTIVE REVIEW OF INDICATIONS AND RESULTS IN 4000 CONSECUTIVE D-DIMER SAMPLES
B. Myers (Queen's Medical Centre, University Hospi, Nottingham, United Kingdom)
 
0909 ASPIRIN AND CLOPIDOGREL RESISTANCE, PLATELET C807T GLYCOPROTEIN IA POLYMORPHISM AND HYPERHOMOCYSTEINEMIA IN SURVIVORS OF MYOCARDIAL INFARCTION
I.G. Gaik, E.H. Hanszke, Z.T. Turowiecka, M.D. Duszynska, K.Z. Zawilska (University of Medical Sciencies, Poznan, Poland)
 
0910 NUMBER AND MIGRATORY ACTIVITY OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH VENOUS THROMBOEMBOLISM
M. Korzh, S.V. Krasnokutskiy, G.I. Kotchuev (Kharkov Medical Academy, Kharkov, Ukraine)
 
0911 SIGNIFICANCE OF PLASMA THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR LEVELS IN PATIENTS WITH VENOUS THROMBOEMBOLISM
I.V. Korzh, I.F. Fedotova, V.D. Nemtsova (Kharkov Medical University, Kharkov, Ukraine)
 
0912 SOLUBLE P-SELECTIN LEVELS IN DIABETES MELLITUS PATIENTS WITH CORONARY ARTERY DISEASE
S. Aref (Mansoura University, Mansoura, Egypt)
 
0913 HR2 HAPLOTYPE IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN LEBANON
R. Mahfouz, Z. Otrock, G. Zaatari, A. Sabbagh, A. Taher, W. Shamseddeen, I. Khalil, Z. Kanaan (American University of Beirut Medical Ct, Beirut, Lebanon)
 
0914 PLATELET GLYCOPROTEIN 1a C807T POLYORPHISM AS A RISK FACTOR FOR CORONARY ARTERY DISEASE: A META-ANALYSIS
A. Tsantes, K. Nikolopoulos, G. Bagos, G. Gialeraki, P. Mantzios, S. Travlou (Attikon Hospital, School of Medicine, Athens, Greece)
 
0915 CORRELATION OF PLATELET GLYCOPROTEIN 1a C807T POLYMORPHISM AND RISK FOR CEREBROVASCULAR DISEASE: A META-ANALYSIS
A. Tsantes, G. Bagos, K. Nikolopoulos, I. Merkouri, S. Travlou (Attikon Hospital, School of Medicine, Athens, Greece)
 
0916 A NOVEL HIGH SHEAR RATE ARTERIAL THROMBOSIS MODEL IN BABOONS
P.N. Badenhorst, S. Lamprecht, J.P. Roodt, S.M. Meiring, K. Silence (University of the Free State, Bloemfontein, South Africa)
 
0917 B-THROMBOGLOBULIN IN CHILDREN WITH POSITIVE FAMILY HISTORY OF CORONARY ARTERY DISEASE
N. Lefkou, E. Ioannidou, S. Vakalopoulou, V. Perifanis, S. Theodoridou, V. Garipidou, M. Athanasiou, I. Tsiouris, I. Klonizakis (Ippokrateion University Hospital, Thessaloniki, Greece)
 
0918 SERUM LEVELS OF SOLUBLE E-SELECTIN IN VENOUS THROMBOEMBOLISM (VTE)
J. Gonzalez-Ordonez, E. Gonzalez, C. Fernandez, M.D. Macias, M.A. Arias, M. Peliz, M. Moran (Hospital San Agustin, Aviles, Spain)
 
0919 NO EFFECT OF B-VITAMIN SUPPLEMENTATION ON MARKERS OF THROMBIN GENERATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
C.A. Rodrigues, R.C. da Silveira, M.A.E. Noguti, V.M. Morelli, V. D'Almeida, A.A. Garcia, F.H.A. Maffei, D.M. Lourenco (Universidade Federal de Sao Paulo, Sao Paulo, Brazil)
 
0920 IMPACT OF A DIAGNOSTIC PROTOCOL FOR DEEP VEIN THROMBOSIS (DVT) ON REQUESTS FOR D-DIMER ASSAYS
J. Bowers, Y.L. Ong, R. McLaughlin (Ulster Hospital, Belfast, United Kingdom)
 
0921 RELATIONSHIP BETWEEN HOMOCYSTEINE LEVELS AND MTHFR GENOTYPE, AND THEIR EFFECT ON DEEP VENOUS THROMBOSIS
L. Pantelidou, A. Agorasti, I. Bazdiara, G. Trypsianis, D. Margaritis, E. Spanoudakis, M. Baka, S. Kotsiopoulou, I. Kotsianidis, D. Konstantinidou, G. Bourikas (Democritus University of Thrace, Alexandroupolis, Greece)
 

PLATELETS / THROMBOCYTOPENIA

 
0922 ADAMTS-13 GENE MUTATION IN A PATIENT WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
A. Falanga, M. Marchetti, M. Noris, S. Nosari, L. Russo, T. Barbui, G. Remuzzi (Hematology Div. Ospedali Riuniti, Bergamo, Italy)
 
0923 IS THE VARIABLE CLINICAL PRESENTATION IN HEREDITARY TTP THE RESULT OF DIFFERENCES IN RESIDUAL ADAMTS13 ACTIVITY?
R. Zahnd, B. Lämmle, J.A. Kremer Hovinga (Central Hematology Laboratory, Bern, Switzerland)
 
0924 INCIDENCE AND LABORATORY FEATURES OF THROMBOCYTOPENIA IN 43 PATIENTS WITH VON WILLEBRAND DISEASE TYPE 2B: CORRELATION WITH MOLECULAR DEFECTS AND ACQUIRED MODIFICATIONS OF VWF
A.B. Federici, L. Baronciani, M.T. Canciani, B. Moroni, F. Gianniello, A. Artoni, C . Balduini, P.M. Mannucci (University of Milan, Milan, Italy)
 
0925 DIFFERENT ACTIVATION STATUS IN PERIPHERAL VERSUS SPLENIC T LYMPHOCYTES IN IMMUNE THROMBOCYTOPENIC PURPURA PATIENTS
M.S. Dilhuydy, P. Blanco, A. Gomez, J.F. Moreau, J.L. Pellegrin, J.F. Viallard (CHU Bordeaux, Bordeaux, France)
 
0926 PREVALENCE AND RELEVANCE OF HEPARIN-INDUCED ANTIBODIES IN LMWH-TREATED PREGNANT WOMEN
U. Harbrecht, E. Forrest, C. Gnida, S. Ohlenforst, B. Rott, J. Rox, J. Oldenburg (Institute of Experimental Haematology, Bonn, Germany)
 
0927 INCREASED PLATELET-MONOCYTE AND PLATELET-NEUTROPHIL COMPLEX FORMATION IN PRIMARY RAYNAUD PHENOMENON AND IN RAYNAUD PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
G.E. Pamuk, B. Turgut, O.N. Pamuk, M. Demir, N. Çakir (Trakya University Medical Faculty, Edirne, Turkey)
 
0928 LOW RATE OF LONG LASTING REMISSIONS AFTER SUCCESSFULL TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH RITUXIMAB
C. Schweizer, J.W. Schmier, A.D. Ho, M. Hensel (University of Heidelberg Medical School, Heidelberg, Germany)
 
0929 AUTOIMMUNE THROMBOCYTOPENIA: FLOW CYTOMETRIC DETERMINATION OF PLATELET-ASSOCIATED CD154/CD40L AND CD40 ON PERIPHERAL BLOOD T AND B LYMPHOCYTES
M. Meabed, S. Omar, G. Taha, K. El-Hadidy (Bani-Suef Faculty of Medcine, Banisuef, Egypt)
 
0930 AGONIST INDUCED PLATELET ACTIVATION IN A HEALTHY POPULATION. STUDY BY FLOW CYTOMETRY
N. Fernandez Mosteirin, C. Salvador Osuna, A. Aranda, M. Torres, J.G. Galache, J.J. Gimeno, A. Godoy, N. Padron, F. Sevil, B. Soria, J.F. Lucia, M. Giralt (Hospital Universitario Miguel Servet, Zaragoza, Spain)
 
0931 EFFICACY AND SAFETY OF IGIV3I GRIFOLS (HUMAN INTRAVENOUS IMMUNOGLOBULIN) IN PATIENTS DIAGNOSED WITH IMMUNE THROMBOCYTOPENIC PURPURA
A. Vidaller, I. Alberca, A. Julia, V. Sandoval, J. Sierra (Hospital Universitario de Bellvitge, Barcelona, Spain)
 
0932 RITUXIMAB IN REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
C.S. Santoro, G. De Angelis, A. De Vellis, A. Guarini, M.L. Milani, A. Rago, R. Foŕ, M.G. Mazzucconi (Hematology, Roma, Italy)
 
0933 ISOLATED THROMBOCYTOPENIAS: "NATURAL" HISTORY OF 281 CASES
G. Frigerio, C. Casartelli, M. Duro, G. Scognamiglio, F. Alberio (Ospedale Valduce, Como, Italy)
 
0934 IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD: REVIEW OF 160 CASES
G. Martinova, O. Muratovska, S. Glamocanin, Z. Antevska-Trajkova, B. Coneska- Jovanova, S. Koceva (University Children's Hospital, Skopje, Macedonia)
 
0935 AUTOIMMUNE THROMBOCYTOPENIA: CLINICAL AND HEMATOLOGICAL OUTCOME OF PATIENTS AFTER DANAZOL ADMINISTRATION AS FIRST LINE OR REFRACTORY DISEASE TREATMENT
E. Kyriakou, CS Chrysohoou, D.M. Dimou, G.P. Grecka, Z.C. Zouvelou, G.G. Georgiou, N.D Ntoufexis, K.M.C Kyrtsonis, P.P. Panayiotidis ("Laikon" University Hospital Of Athens, Athens, Greece)
 
0936 DESCRIPTIVE EPIDEMIOLOGY OF IMMUNE THROMBOCYTOPENIC PURPURA IN THREE EUROPEAN COUNTRIES
J. Satia, J. Acquavella, J. Hollowell, M. Rutstein (University of North Carolina, Chapel Hill, USA)
 
0937 THE SALVAGE TREATMENT WITH CYCLOSPORIN A IN IDIOPATHIC THROMBOCYTOPENIC PURPURA
G.D. Gaman, A.M. Gaman (University of Medicine and Pharmacy, Craiova, Romania)
 

MYELODYSPLASTIC SYNDROMES II

 
0938 EFFECT OF CA2 ANTI-TUMOR NECROSIS FACTOR (TNF) ALPHA ANTIBODY THERAPY ON HAEMOPOIESIS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
A. Boula, M. Voulgarelis, S. Giannouli, G. Katrinakis, M. Psyllaki, C. Pontikoglou, F. Markidou, G. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)
 
0939 RESULTS OF CLONALITY ASSAY AND MEASUREMENT OF APOPTOTIC RATE AND TELOMERE LENGTH SUPPORT USEFULNESS OF SEPARATION OF REFRACTORY CYTOPENIA FROM REFRACTORY ANEMIA AS A DISTINCT SUBTYPE OF EARLY MDS
J. Cermak, M. Belickova, L. Marinov, Zuzana Sieglova, K. Michalova (Institute of Hematology, Praha, Czech Republic)
 
0940 INHIBITION OF THE MKK3-P38 MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY IS REQUIRED FOR NEUTROPHIL DIFFERENTIATION OF HUMAN CORD BLOOD DERIVED CD34+ CELLS
C.R. Geest, C. Geest, M. Buitenhuis, E. Vellenga, P.J. Coffer (UMC Utrecht, Utrecht, The Netherlands)
 
0941 MITOCHONDRIAL INVOLVEMENT IN 5-AZACYTIDINE-INDUCED APOPTOSIS
R. Khan, J. Schmidt-Mende, V. Gogvadze, M. Grövdal, A. Forsblom, M. Hassan, B. Zhivotovsky, E. Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden)
 
0942 CLINICAL CHARACTERISTICS AND TREATMENT OF 217 NEW MDS PATIENTS DURING THE YEAR 2005 IN A TERTIARY REFERRAL CENTER
U. Germing, S. Knipp, C. Strupp, A. Kuendgen, S. Balleisen, H.K. Habersang, F.F. Fox, A.M. Aivado, C.A. Andresen, G.K. Kobbe, B. Hildebrandt, N. Gattermann, R. Haas (University of Düsseldorf, Düsseldorf, Germany)
 
0943 ACQUIRED ALPHA-THALASSEMIA IN MDS (AT-MDS): RARE MUTATIONS DETECTED IN TWO FEMALES
P.S. Haas, M. Schwabe, C.H. Fisher, R. Gibbons, D.R. Higgs, E. Bisse, M. Lübbert (University of Freiburg Medical Center, Freiburg, Germany)
 
0944 SERIAL DETERMINATION OF FLT3 MUTATIONS IN MDS PATIENTS AT DIAGNOSIS, FOLLOW UP, OR AML TRANSFORMATION: FLT3 ITD/ASP835 MUTATIONS INCIDENCE AND THEIR PROGNOSTIC SIGNIFICANCE
G. Georgiou, V. Karali, C. Zouvelou, E. Kyriakou, M. Dimou, S. Chrisochoou, P. Greka, A. Efthymiou, K. Lilakos, L. Petrikkos, K. Dima, E. Basta, P. Panayiotidis (Laikon Hospital, Athens, Greece)
 
0945 ABNORMAL PERIPHERAL BLOOD PROGENITORS ARE CONSISTENTLY OBSERVED AFTER CELL CULTURE IN MYELODYSPLATIC SYNDROME (MDS), ALLOWING THE DIAGNOSIS OF EARLY STEP OF THE DISORDER
I. Dobo, S. Hainos-Godon, F. Genevičve, J. Gérard, M. Gardembas, A. Schmidt- Tanguy, M. Hunault-Berger, M. Zandecki, A. Godon (University Hospital, Angers, France)
 
0946 INCIDENCE OF MDS WITH 5Q- KARYOTYPE ANOMALIES
U. Germing, C. Strupp, B. Hildebrandt, A. Kuendgen, A. Giagounidis, C. Aul, N. Gattermann, R. Haas (University of Düsseldorf, Düsseldorf, Germany)
 
0947 ALTERATIONS IN THE NATURAL KILLER CELL RECEPTOR REPERTOIRE IN MYELODYSPLASTIC SYNDROMES
B.C. Baumann, M. Jädersten, Y.T. Bryceson, M. Grövdal, N. Björkström, E. Hellström-Lindberg, H.G. Ljunggren, K.J. Malmberg (Karolinska Institutet, Stockholm, Sweden)
 
0948 MYELOID ANTIGEN EXPRESSION ON CD34 POSITIVE BLASTS IN MYELODYSPLASTIC SYNDROMES
B. Leus, W. Renmans, K. Jochmans, H. Schots, I. van de Broeck, F. Trullemans, I. van Riet, M. de Waele (AZ-VUB, Brussels, Belgium)
 
0949 LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) FROM PIEMONT MDS REGISTRY: A COMPARATIVE REVIEW OF BONE MARROW ASPIRATE SMEARS AND BONE MARROW BIOPSY SPECIMENS
M. Bonferroni, L. Godio, F. Giordano, D. Ferrero, F. Salvi, C. Paparo, R. Calvi, M. Grasso, A. Levis, A. Gallamini (Hematology, Cuneo, Italy)
 
0950 OCCURRENCE OF THE JAK2 V617F MUTATION IN PATIENTS WITH REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS ASSOCIATED WITH THROMBOCYTOSIS (RARST)
A.F. Remacha, G. Puget, C. Estivill, M.P. Sarda, C. Canals, J. Nomdedeu (Hospital de Sant Pau, Barcelona, Spain)
 
0951 WT1 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A USEFUL MOLECULAR MARKER FOR RISK ASSESSMENT
S. Improta, L. Petriccione, M. Sansone, M.R. Villa, M. Sagristani, A. Lucania, M. Esposito, C. Tiberi, A. Russo, M.T. Polistina, L. Mastrullo (PO San Gennaro, Naples, Italy)
 
0952 COST-EFFECTIVENESS OF CHELATION THERAPY WITH DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSIONDEPENDENT MYELODYSPLASTIC SYNDROME
E. Delea, J.F. Baladi, S.K. Thomas, P.D. Phatak (Policy Analysis Inc. (PAI), Brookline, Ma, USA)
 
0953 MYELODYSPLASTIC SYNDROMES (MDS) PRACTICES AND TREATMENT SURVEY
G.J. Mufti (King's College Hospital, London, United Kingdom)
 
0954 DISPARITIES IN CRITERIA FOR INITIATING CHELATION THERAPY FOR IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
P. Fenaux (Hôpital Avicenne, University Paris XIII, Bobigny, France)
 

CHRONIC MYELOPROLIFERATIVE DISORDERS II

 
0955 ESSENTIAL THROMBOCYTHEMIA AND PREGNANCY: PRELIMINARY REPORT OF THE PREGNANCY COMMITTEE OF THE REGISTRO ITALIANO TROMBOCITEMIE ( RIT )
L. Melillo, A. Tieghi, A. Candoni, R. Ciancia, V. Martinelli, R. Latagliata, G. Specchia, P.R. Scalzulli, R. Fanci, G. Comitini, N. Cascavilla, L. Gugliotta (Casa Sollievo della Sofferenza IRCCS, S. Giovanni Rotondo, Italy)
 
0956 EFFICACY AND SAFETY OF PEGYLATED INTERFERON ALPHA IN PATIENTS WITH POLYCYTHEMIA VERA. A PROSPECTIVE MULTICENTER PHASE II STUDY
K. Merx, A. Fabarius, M. Emig, M. Schatz, H.L. Pahl, B. Stade, H. Kreipe, A. Schmitt-Gräff, J. Thiele, M. Griesshammer, R. Hehlmann, A. Reiter, A. Hochhaus, E. Lengfelder (Universitätsklinikum Mannheim, Mannheim, Germany)
 
0957 RELATION BETWEEN PROPORTION OF GRANULOCYTE JAK2 (V617F) MUTANT ALLELES, CLINICAL PHENOTYPE AND DISEASE PROGRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS
M. Cazzola, F. Passamonti, E: Rumi, D. Pietra, S. Boggi, C. Elena, M.G. Della Porta, L. Arcaini, E. Boveri, C. Pascutto, M. Bonfichi, M. Lazzarino (University of Pavia, Pavia, Italy)
 
0958 HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE. AN ITALIAN GIMEMA RETROSPECTIVE STUDY ON 989 PATIENTS
M. Vannucchi, G. Barosi, A. Rambaldi, R. Marchioli, T. Barbui, M.P.D. Gimema (University of Florence, Florence, Italy)
 
0959 WHAT IS THE BEST STRATEGY FOR THE DIAGNOSIS OF POLYCYTHEMIA VERA?
F. Girodon, P. Mossuz, E. Lippert, N. Boiret, I. Dobo, J.F. Leseves, V. Praloran, M. Donnard, S. Hermouet (Laboratoire d'hématologie, Dijon, France)
 
0960 PREVALENCE OF THE JAK2 V617F MUTATION IN PATIENTS WITH SPLANCHNIC OR CEREBRAL VENOUS THROMBOSIS AND WITHOUT SIGNS OF OVERT CHRONIC MYELOPROLIFERATIVE DISORDER
V. De Stefano, A. Fiorini, E. Rossi, T. Za, G. Farina, G. Reddiconto, P. Chiusolo, S. Sica, G. Leone (Catholic University, Rome, Italy)
 
0961 ASSAY OF THE STROMAL CELLS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES
L.P. Ludmila, G.Y.U. Miterev, K.S. Momotjuk, M.V. Vakhroucheva, N.V. Tzvetaeva, M.S. Sokolova, A. Turkina, N.D. Khoroshko (National Hematology Research Centre, Moscow, Russian Federation)
 
0962 GENE EXPRESSION PROFILING IN ESSENTIAL THROMBOCYTHEMIA USING CDNA MICROARRAY TECHNOLOGY. PRELIMINARY RESULTS
E. Puigdecanet, B. Espinet, B. Bellosillo, J. Lozano, E. Gimeno, E. Abella, A. Salar, L. Sumoy, F. Solé, C. Besses, S. Serrano, L. Florensa (Hospital del Mar, Barcelona, Spain)
 
0963 DEVELOPMENT AND CLINICAL CORRELATES OF A QUANTITATIVE ARMS ASSAY FOR V617F MUTATED JAK2 RNA IN CHRONIC MYELOPROLIFERATIVE DISORDERS
P. Guglielmelli, A. Pancrazzi, E. Antonioli, V. Ponziani, S. Mappa, C. Bogani, L. Pieri, G. Poli, A. Bosi, A.M. Vannucchi (Az. Ospedaliero Universitaria Careggi, Florence, Italy)
 
0964 MOLECULAR ANALYSES IN FAMILIAL AND SPORADIC CONGENITAL PRIMARY ERYTHROCYTOSIS
H. Cario, S. Rives Sola, A. Neusuess, E. Kohne, K. Schwarz (University of Ulm, Ulm, Germany)
 
0965 THE LEVELS OF JAK2V617F RNA DICTATE THE CLINICAL PHENOTYPE IN POLYCYTHEMIA VERA AND IDENTIFIES PATIENTS WITH MORE SYMPTOMATIC DISEASE
E. Antonioli, P. Guglielmelli, S. Mappa, A. Pancrazzi, C. Bogani, V. Ponziani, L. Pieri, G. Longo, A. Bosi, A.M. Vannucchi (Az Ospedaliero-Univarsitaria Careggi, Florence, Italy)
 
0966 DIAGNOSIS OF ESSENTIAL THROMBOCYTHEMIA: THE USEFULNESS OF JAK2 V617F MUTATION DETECTION IN PLATELET'S RNA
O.A. Calendini, C. Marzac, I. Teyssandier, A. Vandamme, F. Delhommeau, O. Legrand, N Casadevall (Hôpital Hôtel-Dieu, Paris, France)
 
0967 UPDATE OF THE GERMAN ESSENTIAL THROMBOCYTHAEMIA (ET) STUDY: INCIDENCE OF COMPLICATIONS DURING LONGTERM FOLLOW-UP
M. Griesshammer, E. Lengfelder, R. Hehlmann, A. Reiter, H. Beneke, H. Gisslinger, H. Döhner, H. Heimpel (University of Ulm, Ulm, Germany)
 
0968 A PHASE II STUDY OF NILOTINIB (AMN107), A NOVEL TYROSINE KINASE INHIBITOR, ADMINISTERED TO PATIENTS WITH SYSTEMIC MASTOCYTOSIS (SM)
A. Hochhaus, N. Gattermann, O.G. Ottmann, P.H. Erben, M. Schatz, T. Schimansky, T. Rafferty, L. Alland, A. Gratwohl, G. Follows, G. Verhoef (Fak.Klin.Med.Mannheim, Mannheim, Germany)
 
0969 IMATINIB-MESYLATE THERAPY FOR SYSTEMIC MASTOCYTOSIS: RELATIONSHIP TO C-KIT MUTATIONAL STATUS
P. Musto, M. Rondoni, P. Piccaluga, S. Soverini, S. Paolini, A. Falcone, G. Sanpaolo, M.L. Barone, C. Musto, R. Guariglia, L. Ciuffreda, G. Pietrantuono, P. Vivaldi, F. Lauria, M. Baccarani, G. Martinelli (CROB, Rionero, Italy)
 
0970 SDF1-3A POLYMORPHISM IN MYELOFIBROSIS WITH MYELOID METAPLASIA: GENOTYPE-PHENOTYPE CORRELATION
M. Marchetti, M.L. Biondi, M. Massa, R. Campanelli, G. Bergamaschi, E. Bonetti, V. Rosti, A. Pecci, G. Gerli, G. Barosi, R.I.M.M. On behalf of the (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0971 TOPOGRAPHY OF INTRAMEDULLARY HEMATOPOIESIS IN MYELOFIBROSIS WITH MYELOID METAPLASIA: RELEVANCE OF 99TC-BW250/183 IMMUNOSCINTIGRAPHY
M. Marchetti, C. Aprile, B. Gerco, G. Barosi, R.I.M.M. On behalf of the (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0972 THE REGISTRO ITALIANO TROMBOCITEMIE (RIT): PRELIMINARY ANALYSIS OF THE FIRST 650 ENROLLED PATIENTS
L. Gugliotta, A. Tieghi, S. Franceschetti, C. Santoro, P. Carluccio, R. Ciancia, E. Rumi, F. Palmieri, E. Antonioli, D. Cilloni, F. Radaelli, N. Vianelli, M.R. Villa, A.B. Federici, M.L. Randi, A. Candoni (Hematology, Reggio Emilia, Italy)
 
0973 FAMILIAL CHRONIC MYELOPROLIFERATIVE DISORDERS (CMD): CLINICAL PHENOTYPE AND JAK2 (V617F) MUTATION STATUS
F. Passamonti, E. Rumi, D. Pietra, S. Boggi, C. Elena, L. Arcaini, M. Della Porta, M. Bonfichi, E. Boveri, C. Pascutto, M. Lazzarino, M. Cazzola (IRCCS Policlinico S. Matteo Pavia, Pavia, Italy)
 
0974 SPANISH REGISTRY OF ESSENTIAL THROMBOCYTHEMIA
M. Giralt, C. Besses, C. Burgaleta, F. Carbonell, L. Hernández-Nieto, G. Ramírez, On behalf of GEMFIN (Gemfin, Zaragoza, Spain)
 
[ Top of page ]


EHA Executive Office, Westblaak 71, 3012 KE Rotterdam, The Netherlands | Phone: (+31) 10-4361760 | Email:

COPYRIGHT © EUROPEAN HEMATOLOGY ASSOCIATION